<SEC-DOCUMENT>0001193125-12-064391.txt : 20120216
<SEC-HEADER>0001193125-12-064391.hdr.sgml : 20120216
<ACCEPTANCE-DATETIME>20120216081246
ACCESSION NUMBER:		0001193125-12-064391
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		5
CONFORMED PERIOD OF REPORT:	20120216
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20120216
DATE AS OF CHANGE:		20120216

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AMARIN CORP PLC\UK
		CENTRAL INDEX KEY:			0000897448
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			X0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	333-176897
		FILM NUMBER:		12617720

	BUSINESS ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000
		BUSINESS PHONE:		353 1 6699 020

	MAIL ADDRESS:	
		STREET 1:		FIRST FLOOR, BLOCK 3, THE OVAL,
		STREET 2:		SHELBOURNE ROAD, BALLSBRIDGE
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			00000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMARIN PHARMACEUTICALS PLC
		DATE OF NAME CHANGE:	20000201

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ETHICAL HOLDINGS PLC
		DATE OF NAME CHANGE:	19930322
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d302169d8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 8-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P> <P STYLE="margin-top:4px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>UNITED STATES </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>SECURITIES AND EXCHANGE COMMISSION </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>WASHINGTON, D.C. 20549 </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="5"><B>FORM 8-K
</B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="4"><B>CURRENT REPORT </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="3"><B>Pursuant to Section&nbsp;13 or 15(d) of the </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Securities Exchange Act of
1934 </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="3"><B>Date of Report (Date of Earliest Event Reported): February&nbsp;16, 2012 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center> <P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="6"><B>Amarin Corporation plc </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>(Exact name of registrant as specified in its charter) </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD WIDTH="34%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>England and Wales</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>0-21392</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not applicable</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(State or other jurisdiction</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>of incorporation)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Commission</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>File Number)</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(I.R.S. Employer</B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Identification No.)</B></FONT></P></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>2 Pembroke House, Upper Pembroke Street 28-32,</B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:1px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dublin 2, Ireland</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not applicable</B></FONT></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Address of principal executive offices)</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>(Zip Code)</B></FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Registrant&#146;s telephone number, including area code: +353 1 6699 020 </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Not Applicable </B></FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="1"><B>Former name or former address, if changed since last report </B></FONT></P> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P><center>
<P STYLE="line-height:6px;margin-top:0px;margin-bottom:2px;border-bottom:1pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Written communications pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Soliciting material pursuant to Rule&nbsp;14a-12 under the Exchange Act (17 CFR 240.14a-12) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Pre-commencement communications pursuant to Rule&nbsp;13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) </FONT></TD></TR></TABLE>
<P STYLE="font-size:8px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="line-height:0px;margin-top:0px;margin-bottom:0px;border-bottom:0.5pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3px;margin-top:0px;margin-bottom:2px;border-bottom:0.5pt solid #000000">&nbsp;</P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;5.02</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
</B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Appointment of President of Research and Development, Senior Vice President </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On February&nbsp;8, 2012, Amarin Corporation plc (the &#147;Company&#148;) entered into an employment agreement with Steven B. Ketchum,
Ph.D (the &#147;Ketchum Agreement&#148;) appointing Dr.&nbsp;Ketchum as the Company&#146;s President of Research and Development, Senior Vice President, effective February&nbsp;16, 2012. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Ketchum served as Senior Vice President, Research and Development of Sunesis Pharmaceuticals, Inc. from June 2008 to February
2012 and as Senior Vice President, Research&nbsp;&amp; Development and Medical Affairs of Reliant Pharmaceuticals, Inc. from May 2005 to May 2008. Dr.&nbsp;Ketchum joins Amarin with 20 years of experience in late-stage product development and
clinical regulatory strategy, having led the filings of multiple new drug applications (&#147;NDAs&#148;) and supplemental NDAs with the U.S. Food and Drug Administration. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the Ketchum Agreement, Dr.&nbsp;Ketchum will report to the Company&#146;s Chief Executive Officer, and his base annual salary will be $372,000. Dr.&nbsp;Ketchum&#146;s will also receive a
one-time signing bonus of $31,900, and going forward he will be eligible to receive an annual performance bonus targeted at 35% of his base salary, with the actual amount of such bonus, if any, to be determined by the Board of Directors.
Dr.&nbsp;Ketchum will also be entitled to continue to participate in the benefits and insurance programs generally available to all Company employees. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">In connection with his hiring, Dr.&nbsp;Ketchum will receive nonqualified options to purchase 600,000 shares of the Company&#146;s ordinary shares represented by American Depositary Shares with a 10-year
term and an exercise price equal to the closing price of the Company&#146;s American Depositary Shares on the NASDAQ Global Market on the date of grant. Twenty-five percent of the options vest on the first anniversary of the grant date with the
remaining seventy-five percent to vest ratably over the subsequent 36-month period, subject to Dr.&nbsp;Ketchum&#146;s continued employment with the Company over such period. This equity award was made in accordance with NASDAQ Listing Rule
5635(c)(4) as an inducement material to Dr.&nbsp;Ketchum&#146;s entering into employment with the Company. The grant, which was made outside the Company&#146;s 2011 Stock Incentive Plan, was approved by the Remuneration Committee of the
Company&#146;s Board of Directors. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Ketchum Agreement provides further that, if Dr.&nbsp;Ketchum is terminated without
cause, he will be entitled to severance as follows: continuation of base salary for six (6)&nbsp;months; continuation of group health plan benefits for up to six (6)&nbsp;months to the extent authorized by and consistent with COBRA; and six
(6)&nbsp;months of accelerated vesting on all outstanding equity incentive awards to the extent subject to time-based vesting. If Dr.&nbsp;Ketchum is terminated without cause or he quits for good reason, in either case, within twenty-four
(24)&nbsp;months following a change in control, then he will be entitled to severance as follows: continuation of base salary for twelve (12)&nbsp;months; continuation of group health plan benefits for up to twelve (12)&nbsp;months to the extent
authorized by and consistent with COBRA; a lump sum cash payment equal to the full target annual performance bonus for the year during which the termination occurred; and 100% acceleration of vesting on all outstanding equity inventive awards. All
references to &#147;cause,&#148; &#147;good reason&#148; and &#147;change in control&#148; are as defined in the Ketchum Agreement. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">The foregoing summary of the Ketchum Agreement is qualified in its entirety by reference to the complete text of the Ketchum Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on
Form 8-K and is incorporated herein by reference. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B><I>Designation of Executive Officers </I></B></FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with Dr.&nbsp;Ketchum&#146;s appointment, effective as of February&nbsp;16, 2012, the Board of Directors of the Company
reviewed the Company&#146;s organizational reporting structure and designated the following individuals as &#147;executive officers&#148; of the Company as such term is defined under Rule 3b-7 under the Securities Exchange Act of 1934, as amended,
or the Exchange Act, and &#147;officers&#148; as such term is defined under Rule 16a-1(f) of the Exchange Act: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joseph S.
Zakrzewski, Chief Executive Officer and Executive Chairman (principal executive officer) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">John F. Thero, President and
Assistant Secretary (principal financial and accounting officer) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Paul E. Huff, Senior Vice President, Chief Commercial Officer
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joseph T. Kennedy, Senior Vice President, General Counsel and Secretary, Chief Compliance Officer </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven B. Ketchum, Ph.D, President of Research and Development, Senior Vice President </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px; margin-left:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stuart Sedlack, Senior Vice President, Corporate Development </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Other than Dr.&nbsp;Ketchum, none of the above-listed executive officers have entered into new contracts or arrangements with the Company in connection with the new designations. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with the foregoing, effective as of February&nbsp;16, 2012, Paresh Soni, M.D., Ph.D., and Frederick W. Ahlholm will no
longer be designated as &#147;executive officers&#148; of the Company as defined under Rule 3b-7 under the Exchange Act or &#147;officers&#148; as defined under Rule 16a-1(f) of the Exchange Act, and Mr.&nbsp;Ahlholm will no longer be designated as
the Company&#146;s principal accounting officer. Both Dr.&nbsp;Soni and Mr.&nbsp;Ahlholm will continue to serve the Company in their current full-time positions. Dr.&nbsp;Soni will continue to provide broad support for the AMR101 program as Senior
Vice President, Head of Development. Mr.&nbsp;Ahlholm&#146;s scope of responsibilities with the Company as Vice President, Finance, will not otherwise change. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">No change has been made to Mr.&nbsp;Thero&#146;s compensation as a result of his appointment as principal accounting officer. There are no family relationships between Mr.&nbsp;Thero with any other
executive officers of the Company or members of the Board of Directors, and he has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item&nbsp;404(a) of Regulation S-K. </FONT></P>
<P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;8.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Other Events </B></FONT></TD></TR></TABLE> <P STYLE="margin-top:6px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On
February&nbsp;16, 2012, the Company issued a press release announcing the appointment of Dr.&nbsp;Ketchum as President of Research and Development, Senior Vice President. The full text of this press release is filed as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference. </FONT></P> <P STYLE="font-size:18px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Item&nbsp;9.01</B></FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Financial Statements and Exhibits. </B></FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(d)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Exhibits: </FONT></TD></TR></TABLE> <P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Letter Agreement with Dr. Steven B. Ketchum, dated February 8, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated February 16, 2012</FONT></TD></TR>
</TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>SIGNATURES </B></FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="45%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="3%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR>
<TD VALIGN="top"> <P STYLE="text-indent:2.00em"><FONT STYLE="font-family:Times New Roman" SIZE="2">Date: February&nbsp;16, 2012</FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amarin Corporation plc</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">By:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ John Thero</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">John Thero</FONT></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">President</FONT></TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>EXHIBIT INDEX </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1px solid #000000;width:25pt" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Exhibit<BR>No.</B></FONT></P></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1px solid #000000;width:39pt"><FONT STYLE="font-family:Times New Roman" SIZE="1"><B>Description</B></FONT></P></TD></TR>


<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">10.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Letter Agreement with Dr. Steven B. Ketchum, dated February 8, 2012</FONT></TD></TR>
<TR>
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top" NOWRAP><FONT STYLE="font-family:Times New Roman" SIZE="2">99.1</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Press Release, dated February 16, 2012</FONT></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d302169dex101.htm
<DESCRIPTION>LETTER AGREEMENT WITH DR. STEVEN B. KETCHUM
<TEXT>
<HTML><HEAD>
<TITLE>Letter Agreement with Dr. Steven B. Ketchum</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 10.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g302169logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 Roosevelt Ave, 3</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mystic, CT 06355 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 860-572-4979 Fax: 860-572-4940 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">February&nbsp;8, 2012 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven&nbsp;B.&nbsp;Ketchum Ph. D </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">49 Canoe
Brook Lane </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Far Hills, NJ 07931-2808 </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dear Steven: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">On behalf of
Amarin Corporation plc (the &#147;Company&#148;), I am pleased to offer employment to you. The purpose of this letter is to outline the terms for your employment. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">1. <B>Position:</B> Your initial position with the Company will be President of Research and Development, Senior Vice President, reporting to Joseph Zakrzewski, Chief Executive Officer. This is a
full-time position as an executive officer of the Company at the Senior Vice President level. It is understood and agreed that, while you render services to the Company, you will not engage in any other employment, consulting or other business
activities (whether full-time or part-time) and that on or before the Start Date you will resign from all other employment and consulting arrangements. Notwithstanding the foregoing, you may engage in religious, charitable, or other community
activities so long as such services or activities do not interfere or conflict with your obligations to the Company. Notwithstanding the foregoing, you may serve on the Board of Directors, as a member or observer, of your previous employer, Sunesis
Pharmaceuticals, Inc. (&#147;Sunesis&#148;), provided such services or activities do not interfere or conflict with your obligations to the Company (&#147;Sunesis Services&#148;), and to the extent there is a scheduling conflict between a Company
event (<I>e.g.</I>, phone conference, meeting, etc.) and an event related to the Sunesis Services, the Company event shall take priority. In addition to your role as President of Research and Development, Senior Vice President of the Company, you
acknowledge and agree that you may be required, without additional compensation, to perform duties for certain affiliated entities of the Company, including without limitation Amarin Pharma, Inc., and to accept any reasonable office or position with
any such affiliate as the Company&#146;s Board of Directors may require, including, but not limited to, service as an officer or director of any such affiliate. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">2. <B>Start Date:</B> Unless otherwise agreed, your first day of employment will be February&nbsp;16, 2012. Your actual first day of employment shall be referred to herein as the &#147;Start Date.&#148;
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B></B>3. <B>Work Location: </B>Your principal place of employment will be the Company&#146;s offices which are currently
located in Bedminster, New Jersey, subject to business travel requirements. <B> </B></FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g302169logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 Roosevelt Ave, 3</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mystic, CT 06355 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 860-572-4979 Fax: 860-572-4940 </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">4. <B>Salary:</B> The Company will pay you a salary at the annual rate of $372,000,
subject to periodic review and adjustment at the discretion of the Company. Currently our policy is to make salary payments semi-monthly. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">5. <B>Bonuses:</B> If your first day of employment with the Company is on or before February&nbsp;16, 2012, the Company will pay you $31,900 as a signing bonus (the &#147;Signing Bonus&#148;). The Signing
Bonus, if applicable, would be payable to you in a lump sum, less required withholding taxes, within 30 days after your Start Date provided you are then employed with the Company. You will also be eligible to receive annual performance bonuses. The
Company will target the bonus of up to 35% of your annual salary rate. The actual bonus is discretionary and will be subject to the Company&#146;s assessment of your performance, as well as business conditions at the Company. The bonus also will be
subject to your employment for the full period covered by the bonus, approval by and adjustment at the discretion of the Company&#146;s Board of Directors or an authorized committee thereof, and the terms of any applicable bonus plan. The Company
may also make adjustments in the targeted amount of your annual performance bonus. Any bonus awarded to you will be paid by March&nbsp;15 of the year following the bonus year to which such bonus relates. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">6. <B>Benefits:</B> You will be eligible to participate in the employee benefits and insurance programs generally made available to its
full-time employees, including health, life, disability and dental insurance. You will be eligible for up to fifteen (15)&nbsp;days of paid vacation per year, which shall accrue on a prorated basis. Other provisions of the Company&#146;s vacation
policy are set forth in the policy itself. You will be reimbursed for all reasonable business expenses you incur while carrying out your duties on behalf of the Company; provided such reimbursement shall be conditioned on you following the
Company&#146;s reimbursement policies and claims procedure, including by providing reasonable documentation of such expenses. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">7. <B>Stock Options: </B>The Remuneration Committee of the Board of Directors of the Company (the &#147;Remuneration Committee&#148;) has
authorized the grant to you, subject to your commencement of full-time employment with the Company, a 10-year non-qualified option to purchase 600,000 Ordinary Shares, par value &pound;0.50&nbsp;per share (and represented by American Depository
Shares, or ADSs), with an exercise price equal to the closing price of the Company&#146;s ADSs on the NASDAQ Capital Market on the date of grant, which in the case of this award shall be the first day of the month following the Start Date that is
also a trading day on the NASDAQ Capital Market. Of these shares 25% shall vest on the one year anniversary of the Start Date with the remaining 75% to vest ratably over the subsequent 36 months. This non-qualified option is intended to qualify as a
so-called &#147;inducement grant&#148; under Nasdaq Marketplace Rule 5635 and as such shall not be issued under the Company&#146;s 2011 Stock Incentive Plan. The terms and conditions of such award shall be set forth in a non-qualified stock option
agreement (the &#147;Equity Document&#148;) that is expected to substantially reflect the various terms and conditions of the Company&#146;s 2011 Stock Incentive Plan (the &#147;2011 Option Plan&#148;). </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">2 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g302169logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 Roosevelt Ave, 3</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mystic, CT 06355 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 860-572-4979 Fax: 860-572-4940 </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">8. <B>At-will Employment, Accrued Obligations; Severance:</B> Your employment is
&#147;at will&#148; meaning you or the Company may terminate it at any time for any or no reason. In the event of the termination of your employment for any reason, the Company shall pay you the Accrued Obligations, defined as (1)&nbsp;your base
salary through the date of termination, (2)&nbsp;an amount equal to the value of your accrued unused vacation days, if any, and (3)&nbsp;the amount of any business expenses properly incurred by you on behalf of the Company prior to any such
termination and not yet reimbursed, provided if the Repayment Obligation applies you authorize the Company to deduct the Repayment Obligation from the Accrued Obligations to the extent permitted by law and you shall be required to pay the remainder
of the Repayment Obligation, if any, within ten (10)&nbsp;days of the last day of your employment (&#147;Date of Termination&#148;). In addition to the Accrued Obligations, in the event the Company terminates your employment without Cause at any
time, or during the twenty-four (24)&nbsp;month period that immediately follows a Change of Control (the &#147;Post-Change in Control Period&#148;) the Company terminates your employment without Cause or you terminate your employment for Good Reason
(defined below), the Company shall provide you with the following termination benefits (the &#147;Termination Benefits&#148;), depending on the Date of Termination: </FONT></P> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(i)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">continuation of your base salary then in effect during the &#147;Salary Continuation Period&#148; which shall be either: (A)&nbsp;six (6)&nbsp;months from the Date of
Termination, if the Company terminates your employment without Cause and the Date of Termination occurs at any time outside of the Post-Change in Control Period, or (B)&nbsp;twelve (12)&nbsp;months from the Date of Termination, if the Company
terminates your employment without Cause or you terminate your employment for Good Reason and, in either case, the Date of Termination occurs during the Post-Change in Control Period. Solely for purposes of Section&nbsp;409A of the Internal Revenue
Code of 1986, as amended, each Salary Continuation Payment during the Salary Continuation Period is considered a separate payment; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(ii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">continuation of group health plan benefits to the extent authorized by and consistent with 29 U.S.C. &#167; 1161 et seq. (commonly known as &#147;COBRA&#148;), with the
cost of the regular premium for such benefits shared in the same relative proportion by the Company and you as in effect on the date of termination until the earlier of: (i)&nbsp;the end of the Salary Continuation Period, and (ii)&nbsp;the date you
become eligible for health benefits through another employer or otherwise become ineligible for COBRA; </FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iii)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">if the Company terminates your employment without Cause or you terminate your employment for Good Reason and, in either case, the Date of Termination occurs during the
Post-Change in Control Period, a lump sum cash payment equal to your target annual performance bonus for the year during which the Date of Termination occurs; </FONT></TD></TR></TABLE>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">3 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g302169logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 Roosevelt Ave, 3</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mystic, CT 06355 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 860-572-4979 Fax: 860-572-4940 </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(iv)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">if the Company terminates your employment without Cause and the Date of Termination occurs outside of the Post-Change in Control Period, six (6)&nbsp;months of
accelerated vesting from the Date of Termination with respect to any of your then outstanding stock options, restricted stock units or other equity incentive awards (in each case, only to the extent subject to time-based vesting); and
</FONT></TD></TR></TABLE> <P STYLE="font-size:6px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left"><FONT STYLE="font-family:Times New Roman" SIZE="2">(v)</FONT></TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">if the Company terminates your employment without Cause or you terminate your employment for Good Reason and, in either case, the Date of Termination occurs during the
Post-Change in Control Period, then outstanding stock options, restricted stock units or other equity incentive awards (whether or not subject to time based vesting) shall immediately vest in full effective upon the Date of Termination.
</FONT></TD></TR></TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Notwithstanding anything to the contrary in this Agreement, you shall not be entitled to any Termination Benefits unless you
first (i)&nbsp;enter into, do not revoke, and comply with the terms of a separation agreement in a form acceptable to the Company which shall include a release of claims against the Company and related persons and entities (the &#147;Release&#148;),
provided that the Release shall not require you to release (a)&nbsp;claims to enforce your right to receive Termination Benefits; (b)&nbsp;claims for vested benefits pursuant to ERISA; (c)&nbsp;claims with respect to your vested equity rights as of
the Date of Termination; (d)&nbsp;claims to enforce the Company&#146;s obligation to indemnify you to the extent such indemnification obligations exist; and (e)&nbsp;claims which legally may not be waived; (ii)&nbsp;resign from any and all
positions, including, without implication of limitation, as a director, trustee, and officer, that you then hold with the Company and any affiliate of the Company; and (iii)&nbsp;return all Company property and comply with any instructions related
to deleting and purging duplicates of such Company property, in each case within the time period designated by the Company but in no event later than 60 days of the Date of Termination. The Salary Continuation Payments shall commence within 60 days
after the Date of Termination and shall be made on the Company&#146;s regular payroll dates; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Salary Continuation Payments shall begin to
be paid in the second calendar year. In the event you miss a regular payroll period between the Date of Termination and first Salary Continuation Payment, the first Salary Continuation Payment shall include a &#147;catch up&#148; payment.
Notwithstanding the foregoing, if you breach any of the material provisions of this Agreement or the Nondisclosure Developments and Non-competition Agreement, in addition to all other rights and remedies, the Company shall have the right to
terminate or cease payment of the Termination Benefits. For the avoidance of doubt, you shall not be entitled to the Termination Benefits in the event your employment ends due to your death or disability. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">4 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g302169logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 Roosevelt Ave, 3</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mystic, CT 06355 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 860-572-4979 Fax: 860-572-4940 </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">9. <B>Definitions: </B>For purposes of this Agreement, the following terms shall have
the following meanings: </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Cause&#148; shall mean: (i)&nbsp;conduct by you constituting an act of material misconduct in connection with
the performance of your duties, including, without limitation, misappropriation of funds or property of the Company other than the occasional, customary and de minimis use of Company property for personal purposes; (ii)&nbsp;the commission by you of
(A)&nbsp;any felony; or (B)&nbsp;a misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii)&nbsp;any conduct by you that would reasonably be expected to result in material injury or reputational harm to the Company or any of its
subsidiaries and affiliates if you were retained; (iv)&nbsp;continued non-performance or continued unsatisfactory performance by you of your responsibilities as reasonably determined by the Company&#146;s Board of Directors; (v)&nbsp;a breach by you
of any of the material provisions of any agreement between you and the Company including, without limitation, any agreement relating to non-disclosure, non-competition or assignment of inventions; (vi)&nbsp;a material violation by you of any of the
Company&#146;s written policies or procedures provided that, other than in the case of noncurable events, you are provided with written notice and fifteen (15)&nbsp;days to cure. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">&#147;Change of Control&#148; shall have the meaning set forth in the 2011 Option Plan, but only to the extent such event also constitutes a &#147;change in ownership&#148; of the Company or a
&#147;change in the ownership of a substantial portion of the Company&#146;s assets&#148; for purposes of Section&nbsp;409A of the Code. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;Good Reason&#148; shall mean that you have complied with &#147;Good Reason Process&#148; (hereinafter defined) following the occurrence of any of
the following Good Reason conditions that occur without your consent: (i)&nbsp;a material diminution of your base salary; (ii)&nbsp;a material diminution in your authority, duties or responsibilities; (iii)&nbsp;a material change in the principal
location where you are required to provide services for the Company (not including business travel and short-term assignments); and/or (iv)&nbsp;a material breach by the Company of this Agreement. For purposes of this Agreement, &#147;Good Reason
Process&#148; shall mean that: (x)&nbsp;you reasonably determine in good faith that a &#147;Good Reason&#148; condition has occurred; (y)&nbsp;you notify the Company in writing of the Good Reason condition within thirty&nbsp;(30) days of the first
occurrence of such condition; (z)&nbsp;you cooperate in good faith with the Company&#146;s efforts, for a period of thirty (30)&nbsp;days following such notice (the &#147;Cure Period&#148;), to remedy the condition; notwithstanding such efforts, the
Good Reason condition continues to exist; and you terminate your employment within thirty (30)&nbsp;days after the end of the Cure Period. If the Company cures the Good Reason condition during the Cure Period, Good Reason shall be deemed not to have
occurred. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">10. <B>Section&nbsp;280G Limitation:</B> Anything in this Agreement to the contrary notwithstanding, in the event
that the amount of any compensation, payment or distribution by the Company to or for the benefit of you, whether paid or payable or distributed or distributable </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">5 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g302169logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 Roosevelt Ave, 3</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mystic, CT 06355 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 860-572-4979 Fax: 860-572-4940 </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section&nbsp;280G of the Code and the applicable regulations thereunder (the &#147;Severance
Payments&#148;), would be subject to the excise tax imposed by Section&nbsp;4999 of the Code, the following provisions shall apply: </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(a) If the Severance Payments, reduced by the sum of (1)&nbsp;the Excise Tax and (2)&nbsp;the total of the Federal, state, and local income and employment taxes payable by you on the amount of the
Severance Payments which are in excess of the Threshold Amount, are greater than or equal to the Threshold Amount, you shall be entitled to the full benefits payable under this Agreement. </FONT></P>
<P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(b) If the Threshold Amount is less than (x)&nbsp;the Severance Payments, but greater than (y)&nbsp;the Severance Payments
reduced by the sum of (1)&nbsp;the Excise Tax and (2)&nbsp;the total of the Federal, state, and local income and employment taxes on the amount of the Severance Payments which are in excess of the Threshold Amount, then the Severance Payments shall
be reduced (but not below zero) to the extent necessary so that the sum of all Severance Payments shall not exceed the Threshold Amount. In such event, the Severance Payments shall be reduced in the following order: (1)&nbsp;cash payments not
subject to Section&nbsp;409A of the Code; (2)&nbsp;cash payments subject to Section&nbsp;409A of the Code; (3)&nbsp;equity-based payments and acceleration; and (4)&nbsp;non-cash forms of benefits. To the extent any payment is to be made over time
(e.g., in installments, etc.), then the payments shall be reduced in reverse chronological order. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">(c) For the
purposes of this Section, &#147;Threshold Amount&#148; shall mean three times your &#147;base amount&#148; within the meaning of Section&nbsp;280G(b)(3) of the Code and the regulations promulgated thereunder less one dollar ($1.00); and &#147;Excise
Tax&#148; shall mean the excise tax imposed by Section&nbsp;4999 of the Code, and any interest or penalties incurred by you with respect to such excise tax. </FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px; margin-left:4%; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">(d) The determination as to which of the alternative provisions of this Section&nbsp;9 shall apply to you shall be made by a nationally recognized accounting firm selected by the Company (the
&#147;Accounting Firm&#148;), which shall provide detailed supporting calculations both to the Company and you within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or
you. For purposes of determining which of the alternative provisions of this Section&nbsp;9 shall apply, you shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the
calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in the state and locality of your residence on the date of termination, net of the maximum reduction in
federal income taxes which could be obtained from deduction of such state and local taxes. Any determination by the Accounting Firm shall be binding upon the Company and you. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">6 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g302169logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 Roosevelt Ave, 3</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mystic, CT 06355 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 860-572-4979 Fax: 860-572-4940 </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">11. <B>Taxes; Section&nbsp;409A:</B> All forms of compensation referred to in this
letter agreement are subject to reduction to reflect applicable withholdings and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that
minimizes tax liabilities. Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section&nbsp;409A of the Code, the Company determines that you are a &#147;specified
employee&#148; within the meaning of Section&nbsp;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement on account of your separation from service would be considered deferred
compensation subject to the 20 percent additional tax imposed pursuant to Section&nbsp;409A(a) of the Code as a result of the application of Section&nbsp;409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be
provided until the date that is the earlier of (A)&nbsp;six months and one day after your separation from service, or (B)&nbsp;your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include
a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by
you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in
which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year.
Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">To the extent that any payment
or benefit described in this Agreement constitutes &#147;non-qualified deferred compensation&#148; under Section&nbsp;409A of the Code, and to the extent that such payment or benefit is payable upon the termination of this Agreement, then such
payments or benefits shall be payable only upon your &#147;separation from service.&#148; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation
Section&nbsp;1.409A-1(h). </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The parties intend that this Agreement will be administered in accordance with Section&nbsp;409A of the Code. To
the extent that any provision of this Agreement is ambiguous as to its compliance with Section&nbsp;409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section&nbsp;409A of the Code. The parties
agree that this Agreement may be </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">7 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g302169logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 Roosevelt Ave, 3</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mystic, CT 06355 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 860-572-4979 Fax: 860-572-4940 </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
amended, as reasonably requested by either party, and as may be necessary to fully comply with Section&nbsp;409A of the Code and all related rules and regulations in order to preserve the
payments and benefits provided hereunder without additional cost to either party. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Company makes no representation or warranty and shall
have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section&nbsp;409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">12. <B>Representation Regarding Other Obligations: </B>This offer is conditioned on your representation that you are not
subject to any confidentiality, non-competition agreement or any other similar type of restriction that may affect your ability to devote full time and attention to your work at the Company. If you have entered into any agreement that may restrict
your activities on behalf of the Company, please provide me with a copy of the agreement as soon as possible. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">13. <B>Other
Terms:</B> Your employment with the Company shall be on an at-will basis. In other words, you or the Company may terminate employment for any reason and at any time, with or without notice, subject to the Termination Benefits provisions herein.
Similarly, the terms of employment outlined in this letter are subject to change at any time. You also will be required to sign the Company&#146;s Nondisclosure Developments and Non-competition Agreement as a condition of your employment, the terms
of which shall be incorporated by reference into this letter agreement. A copy of that Agreement is enclosed. In addition, our offer to you is contingent on the completion of references checks and a background investigation that are satisfactory to
the Company (as determined by the Company) and your submission of satisfactory proof of your identity and your legal authorization to work in the United States and a satisfactory Company-paid initial-employment physical and drug screen. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">14. <B>Interpretation, Amendment and Enforcement:</B> This Agreement, including the Company&#146;s Nondisclosure Developments and
Non-competition Agreement and the Equity Document, constitute the complete agreement between you and the Company, contain all of the terms of your employment with the Company and supersede any prior agreements, representations or understandings
(whether written, oral or implied) between you and the Company. The terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way
connected with, this Agreement, your employment with the Company or any other relationship between you and the Company (the &#147;Disputes&#148;) will be governed by the laws of the State of Connecticut, excluding laws relating to conflicts or
choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the State of Connecticut in connection with any Dispute or any claim related to any Dispute. </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">8 </FONT></P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g302169logo.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px;padding-bottom:0px;" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">12 Roosevelt Ave, 3</FONT><FONT STYLE="font-family:Times New Roman" SIZE="1"><SUP
STYLE="vertical-align:baseline; position:relative; bottom:.8ex">rd</SUP></FONT><FONT STYLE="font-family:Times New Roman" SIZE="2"> Floor </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Mystic, CT 06355 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">Tel: 860-572-4979 Fax: 860-572-4940 </FONT></P>
<p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P>
 <P STYLE="margin-top:0px;margin-bottom:0px; text-indent:4%"><FONT STYLE="font-family:Times New Roman" SIZE="2">15. <B>Assignment: </B>Neither you nor the Company may make any assignment of this
Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement without your consent to one of its
Affiliates or to any person with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets. This Agreement shall inure to the benefit of and
be binding upon you and the Company, and each of our respective successors, executors, administrators, heirs and permitted assigns. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px; text-indent:4%"><FONT
STYLE="font-family:Times New Roman" SIZE="2">We are excited about the opportunity to work with you at Amarin. If you have any questions about this information, please do not hesitate to call. Otherwise, please confirm your acceptance of this offer
of employment by signing below and returning a copy to me no later than February&nbsp;10, 2012. We are confident that with you background and skills, you will have an immediate positive impact on our organization. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>


<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2">Signed for and on behalf of:</FONT></TD></TR>
<TR>
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR>
<TD VALIGN="top" COLSPAN="3"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>AMARIN CORPORATION PLC</B></FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Signed:</FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Joseph Zakrzewski</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Joseph Zakrzewski, Chief Executive Officer</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dated:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">February 8, 2012</FONT></P></TD></TR></TABLE>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">I accept the offer of employment under the terms and conditions stated above. </FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE">


<TR>
<TD WIDTH="10%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="88%"></TD></TR>

<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Signed:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">/s/ Steven B. Ketchum</FONT></P></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><I>Name:</I></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2">Steven B. Ketchum</FONT></TD></TR>
<TR>
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR>
<TD VALIGN="top"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Dated:</B></FONT></TD>
<TD VALIGN="bottom"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="top"> <P STYLE="margin-top:0px;margin-bottom:1px;border-bottom:1px solid #000000"><FONT STYLE="font-family:Times New Roman" SIZE="2">February 8, 2012</FONT></P></TD></TR>
</TABLE> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Enclosures </FONT></P>
 <p STYLE="margin-top:0px;margin-bottom:0px"><FONT SIZE="1">&nbsp;</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2">9 </FONT></P>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>3
<FILENAME>d302169dex991.htm
<DESCRIPTION>PRESS RELEASE
<TEXT>
<HTML><HEAD>
<TITLE>Press Release</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="right"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Exhibit 99.1 </B></FONT></P>
<P STYLE="font-size:12px;margin-top:0px;margin-bottom:0px">&nbsp;</P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center">


<IMG SRC="g302169ex99_1pg01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Amarin Corporation Appoints Dr.&nbsp;Steven Ketchum </B></FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px" ALIGN="center"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>to Head Research and Development and Announces Inducement Grant Under NASDAQ Rule 5635(c)(4) </B></FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">BEDMINSTER, N.J., and DUBLIN, Ireland, Feb. 16, 2012 &#150; Amarin Corporation plc (Nasdaq: AMRN), a late-stage biopharmaceutical company with a focus on
cardiovascular disease, today announced that Steven Ketchum, Ph.D., has been appointed President of Research and Development, Senior Vice President, effective February&nbsp;16, 2012. Dr.&nbsp;Ketchum will be responsible for Amarin&#146;s drug
discovery, preclinical and clinical development program and regulatory and medical affairs activities, including the ongoing development and regulatory review support for Amarin&#146;s lead product candidate, AMR101. </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Ketchum joins Amarin with a significant record of achievement in the life sciences industry, with 20 years of experience in late-stage product
development and clinical regulatory strategy, having led the filings of multiple successful new drug applications (NDAs) and supplemental NDAs. Most recently, Dr.&nbsp;Ketchum served as Senior Vice President, Research and Development for Sunesis
Pharmaceuticals where, as a member of the Executive Committee, he provided strategic direction for all facets of research and development, including clinical strategy and operations, regulatory affairs, and pharmaceutical development. Prior to
Sunesis, Dr.&nbsp;Ketchum was Senior Vice President, Research and Development and Medical Affairs at Reliant Pharmaceuticals with responsibilities for leading the strategic direction and day-to-day operations of Reliant&#146;s clinical research,
product development, and medical affairs departments. Dr.&nbsp;Ketchum has also served as Senior Vice President, Operations and Regulatory Affairs for IntraBiotics Pharmaceuticals, Inc., where he was responsible for regulatory affairs, project
management, quality assurance, and supply chain management in support of late-stage clinical research. Dr.&nbsp;Ketchum also held positions with increasing responsibility in regulatory affairs during his nearly eight-year tenure at ALZA Corporation.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Dr.&nbsp;Ketchum earned a Ph.D. in pharmacology from University College London and a B.S. in biological sciences from Stanford University.
</FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;We are delighted to announce this important appointment and to welcome Steve to Amarin&#146;s executive management team,&#148; stated
Joseph Zakrzewski, Chairman and CEO. &#147;I have known Steve since working with him at Reliant Pharmaceuticals and had the privilege of working with him extensively on Lovaza/Omacor. Steve&#146;s expertise and depth of knowledge in Omega 3 product
development and strong business acumen will serve Amarin well. Steve&#146;s addition reflects Amarin&#146;s optimism for its future as his appointment results in the strengthening of an already strong R&amp;D team.&#148; </FONT></P>
<P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">&#147;This is an exciting time to be joining Amarin. I believe AMR101 has the potential to become the next-generation treatment for patients with
elevated triglyceride levels,&#148; said Dr.&nbsp;Ketchum. &#147;It&#146;s great to be a part of this dynamic company, and I look forward to working with the Amarin team to advance AMR101 through regulatory review to commercialization.&#148;
</FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In connection with this appointment, Amarin granted Dr.&nbsp;Ketchum an inducement equity award in
accordance with NASDAQ Listing Rule 5635(c)(4). The grant, which was made outside the Amarin 2011 Stock Incentive Plan, was approved by the Remuneration Committee of the company&#146;s Board of Directors, and the Board of Directors, as an inducement
material to Dr.&nbsp;Ketchum&#146;s entering into employment with Amarin. The grant to Dr.&nbsp;Ketchum consists of nonqualified options to purchase 600,000 shares of the Amarin ordinary shares represented by American Depositary Shares
(&#147;Shares&#148;) with a 10-year term and an exercise price equal to the closing price of Amarin American Depositary Receipts on the date of grant.&nbsp;Twenty-five percent of the options will vest on the first anniversary of
Dr.&nbsp;Ketchum&#146;s start date with Amarin with the remaining seventy-five percent to vest ratably over the subsequent 36-month period, subject to Dr.&nbsp;Ketchum&#146;s continued employment with Amarin over such period. If, within 24 months of
a change of control of Amarin, Dr.&nbsp;Ketchum is terminated without cause or voluntarily terminates his employment for good reason, he will receive immediate vesting of all outstanding stock options. Dr.&nbsp;Ketchum would receive 6 months of
accelerated vesting if terminated without cause not following a change of control of Amarin or outside of the 24-month period following a change of control. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2"><B>About AMR101 </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">AMR101 (icosapent ethyl) is an ultra pure omega-3 fatty acid, comprising not
less than 96% EPA (icosapent ethyl), that Amarin is developing as a treatment for patients with very high triglyceride levels (<U>&gt;</U>500 mg/dL), and for patients with high triglyceride levels (<U>&gt;</U>200 and &lt;500mg/dL) who are also on
statin therapy for elevated low-density lipoprotein cholesterol, or LDL-C, levels (which we refer to as mixed dyslipidemia). The efficacy and safety of AMR101 were studied in two Phase 3 clinical trials, the MARINE trial, which studied patients with
very high triglyceride levels, and the ANCHOR trial, which studied patients with high triglyceride levels who were also on statin therapy for elevated LDL-C levels. These two Phase 3 clinical trials showed favorable results in triglyceride reduction
compared to placebo in the studied patient populations. Reduction in triglyceride levels was achieved without a statistically significant increase, and in the 4 gram AMR101 ANCHOR results, with a statistically significant decrease, in LDL-C levels.
These trials also showed favorable results, particularly with the 4 gram dose of AMR101, in other important lipid and inflammation biomarkers, including Apo-B, non-HDL-C, Total-Cholesterol, VLDL-C, Lp-PLA2, and hs-CRP. In these trials, AMR101
exhibited a safety profile comparable to placebo. In December 2011, Amarin commenced patient dosing in a cardiovascular outcomes study of AMR101, titled REDUCE-IT (Reduction of Cardiovascular Events with EPA &#150; Intervention Trial), that is
designed to evaluate the efficacy of AMR101 in reducing major cardiovascular events in a high-risk patient population on statin therapy. </FONT></P>
<P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>About Amarin </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amarin Corporation plc is
a late-stage biopharmaceutical company with expertise in lipid science focused on the treatment of cardiovascular disease. Amarin has filed a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) for the use of its lead product
candidate, AMR101, in the treatment of patients with very high triglyceride levels (the population studied in Amarin&#146;s MARINE </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">
trial), and the FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of July&nbsp;26, 2012 for the completion of its review. Amarin plans to separately seek approval for use of AMR101
in the treatment of patients with high triglyceride levels who are also on statin therapy for elevated LDL-C levels, the population studied in the ANCHOR trial, if the FDA approves the MARINE indication and after the REDUCE-IT cardiovascular
outcomes trial is substantially underway. Each of the MARINE, ANCHOR and REDUCE-IT studies is the subject of a Special Protocol Assessment (SPA) agreement with the FDA. Amarin also has next-generation lipid candidates under evaluation in preclinical
development. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Forward Looking Statements </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">This press release contains forward-looking statements, including statements about the potential contribution to Amarin of Dr.&nbsp;Ketchum, the timing of FDA decisions regarding the AMR101 NDA, the
efficacy, safety and therapeutic benefits of AMR101, the potential for AMR101 to become the next-generation treatment for patients with elevated triglyceride levels and the plans of Amarin to seek approval for and commercialize its product
candidates. These forward-looking statements are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual results to differ materially from those described or projected herein include the
following: uncertainties associated generally with research and development, clinical trials and related regulatory approvals; the risk that SPAs are not a guarantee that FDA will approve a product candidate upon submission; and the risk that
historical clinical trial enrollment and randomization rates may not be predictive of future results. A further list and description of these risks, uncertainties and other risks associated with an investment in Amarin can be found in Amarin&#146;s
filings with the U.S. Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and its most recent Quarterly Report on Form 10-Q. Existing and prospective investors are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date hereof. Amarin undertakes no obligation to update or revise the information contained in this press release, whether as a result of new information, future events or circumstances or
otherwise. </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Amarin&#146;s product candidates are in various stages of development and are not available for sale or use outside of approved
clinical trials. Nothing in this press release should be construed as marketing the use of such product candidates. </FONT></P> <P STYLE="margin-top:18px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Investor Contact
Information: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Stephen D. Schultz </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Senior Director, Investor Relations and Corporate Communications </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">Amarin Corporation </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In U.S.: +1 (860)&nbsp;572-4979 x292 </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">investor.relations@amarincorp.com </FONT></P> <P STYLE="margin-top:12px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Lee M. Stern
</FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">The Trout Group </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In U.S.: +1
(646)&nbsp;378-2922 </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">lstern@troutgroup.com </FONT></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2"><B>Media Contact Information: </B></FONT></P> <P STYLE="margin-top:6px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">David Schull or Martina Schwarzkopf, Ph.D. </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">Russo Partners </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">In U.S.: +1 (212)&nbsp;845-4271 or +1 (212)&nbsp;845-4292 (office) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT
STYLE="font-family:Times New Roman" SIZE="2">+1 (347)&nbsp;591-8785 (mobile) </FONT></P> <P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">david.schull@russopartnersllc.com </FONT></P>
<P STYLE="margin-top:0px;margin-bottom:0px"><FONT STYLE="font-family:Times New Roman" SIZE="2">martina.schwarzkopf@russopartnersllc.com </FONT></P>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g302169ex99_1pg01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g302169ex99_1pg01.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`.@$=`P$1``(1`0,1`?_$`.,```("`P`#`0``````
M```````*"0L!!P@"`P8%`0`"`@,!`0``````````````!P8(`0,%!`(0```&
M`0,!!`()"PT,"P````$"`P0%!@<`"`D1(1(3"C$W05$S%!4U-C@Y\&%Q@<$B
M,C1D%K>1L5)B(U-C5&5F=A<9H4*"576U1W=(F(F9X7+"0R569QA823H1``$"
M!`,#!@D#$`D#!0````$"`P`1!`4A,09!41)A<8$B,A.1H;'!0C,4-0=R-!7P
MT>%2LL+2(T-S)$1%A18V\6*"DJ*3TY254[,W8Z/CA"7_V@`,`P$``A$#$0`_
M`'Z-$$&B"#1!'I7510247743110345665.5-))),HG4444.)2$(0A1$1$0``
M#J.L@*4>%.*M@WF/E2@C$X<NZ$>?,#\^]'L-5R'L)V8RL/=$Y[WI`9RS]'.8
M&R4P\0!C+S6-<;%.UEH^=>N%RHI24Z10J+/N*-V?B+&%PW<N@]#5'>HO5X0I
M*<T-X@G^LHX$#<-L+?56IF7&UVNCZX(ZRMF!G(;^>&/.'#?HVY#]BF+<UR1F
M3;)U=36Q?FF+9G9D(UR53&S)"1ETF+,B)(UA<XIPTF6Z`)D(@1\*).\"7>%>
MZNL2K#>ETBIEE?70=Z3E_=Q!B7Z?N8NEM0^9=^.JKGB5`/0&HW';@T00:((-
M$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&B"#1!!H@@T00:((-$$&
MB"#1!!H@@T00:((-$$&B"#1!!H@@T00:((YOWA7G$N-=JVXF\9X31<X;K^&,
MBN<E1RJW@#-U%Q5I)E+UQJH!TSC(V1LY%@U(0?$4<N$RD^^$->^U4]557)BG
MI/G"W$\/(9B1YA'CKW&6J)UQ_P!6&U3Y1+$=,4RM@@Y2&<M5G\!+U]G/,4[#
M74)=LZ1.^KD@X<IQDBR<.6[;X3CEO>QTTW29?"6,D;IZ!`+B,.!Q``4E:TR2
M2/M@!/IBOCJ"%%0!"#B)[IX0P;Y:_D&+LZWQ1V(K[9QAL%[JRQV.K(5Z8/@B
M$R>194N*;4LJH8I8XBLL_5AG*W4J0(2@*K?>MRB1??$JP?2EG-:RG]-I<1RI
M.8B5:/NQH+B*=SYN]U>8[XL[`$!`/M:K;C*<.7#`#;YHSH@@UB8&&V",=0T3
M$IP0=0UF#DC.L3$I[((-9@@U@D)$SE!&.H:SET03@ZAH)`$SE!MEMC.B"#1!
M&.H>WH.&)@C.@&<$8ZZ((.H:(,X.H:/!&"90=0^H!T8`R.9C)PS@ZAHY(Q,0
M==8GLC.R<'4-9GC+;!/">R#J&B">R#J&L3$$'4-$P!.,R,'4-9SC'+!U#01(
M3.4$9].CD@@UB>,H(QU#68">'.#J&B#E@Z_5TT2.X^`P2,'7ZP_J:R<!,Y<Q
M^M&<-X\,`CT#7R%),8&)D(5+\P5DFW[M,[[,.&O!TK*#:=P61Z[DW<4M7CG\
M6K8@B'RZ,2I.=T0;JQ3-BSF;(Z;KB'08-B;NF%9,!9^A*9FUT59JVN0>[8:4
MAF8E-TY\)EFGJC#'K1"-4/N5E2Q9*8GC=7-<O13AGXY\T::\S1Q841?9QB?<
M[M]HQ8*7V:5.L8CLM?K<<F=!UMJ0$D9"NGA$2"[4'%4^JFJ58`$"1TJ^57'N
MI%,3V_#?4[OTR[;JU?$BK45I))]:,0,?MLN<2CRZNL38MS=32)FJG`29#-.\
MRW'$P@,BLJW52<-U5$5T5"*HJHG,DJBHF('2525(8ITU4S@`@8H@("'4-/M;
M84%)(D%)D01"N2I;:II)"AMVSBV)X.^0EAR%[%J%<IE\D?,^)$H_$.<&!EC*
MNEK;6XEH2,N1P5`%3-K_``/@R(GZ=PKTSI$HCX`CJJFLK"Y8+XXR`?97>NV=
MDB?-ES0\=-W3Z4MJ%*]<W)*NC(_VHF*U%(D,:PS/"93LF++Q!X2N\%C;+,G`
MNVM"OEGJQ+M7ZO83B06DI+50[Z."<9)`!@.AXZ?>Z]>O9TUOI54Z*I#E6DKI
MTGK)!D2.0[(TU`>+*DTZN%XC`PFARM<A?/!Q163&#;)&X7;)E&D9B0L_YC7.
MF8-@XIP,A31@OS@B+%69IN+F'>()V-JJB=%R\;KI'']T*<IB`X-+:?T9JA+H
MIV*AM3(!4%.$F2C($$#$3\$+V]774EEX`ZXRKO"920-F^<165+S3?*?&VRM2
M%NMV)+%56-@AW=FK[?$%6C%YR`;2+969B$)1F!74<M)1Q%$2.$Q[Z)C]\O:`
M:E+_`,,=,J8<#27>][M10>\5@J6&S'&.*SK6\AU(>4@M\0GU!@,)Q9"X;RW1
M<\XJQ[F?&4VVL>/\G5&#NE3FFA@.D]AIY@B_:B<H"(HND`5\)9(W0Z2Q#D,`
M&*(!7:JHGJ"K<HW@>\:)!G.<P93QSGF#M&,-RG?;JJ=%2V9MN)!!YQ/HYHV9
MKSDR$XW1%%S.<@COCAV-7S-]14@ULPV&5AL9X3BY](CM@YOUH,X4/+N8P3%&
M3:U"LQ\A+G0,()+F9D14$`5[91I*PC4-Y11.\0I4#B<(PDG<3LF2(X>H+I]%
M6Y50@COC()Y281I#S1_+>'^D?#XAV?Z$:?\`=(/3KIW#X8:3G/NW1M]8K&%I
M_&=\`D%HZ4SAJ#B?R'S5;T<8X*W=9GW0[;JK@&^60D\KBR*P1&R%_NN-X&R.
M86:;GL<:XBX^D2%@4BG230Y#/54$^XJ<H&'PP5^J6-'V=]ZUT=,\JN0)<9<5
M)*L<)83E@9\O)$VLKNH;@TU6//-BF)G()Q(YYX<T,I!Z`TN0)"0RB8QR+O4W
MQ;=-@N%IG-VXV\-*M`M4GC:L5UN9!W<\C69!DJ\:TVA5\ZR*\[/O@2Z#VIM6
MB8BNZ60;D.J7J6FSUU[K!0T""MTYGT4C:5'8!'@N-PI;;3&HJU<*,N4F60YX
M6GXAO,2W/>5R%97PKN+/7L>8LSPHV-M*J0HQO7'MHKJ:;%OC:1MZ#"/>624R
M3#%4?&</3&*,XW][LB(I.DFY6+JOX?-V>Q-5M#QNU329O',&<IJ`V</W,R8B
M-CU8Y<+HNFJ"E-.OU8W;DSY<^>'$@'K^O^KI3`S$XGL`_8Z]@Z#D=N$9B#CD
MKN'+?MIH>Y'=+MOSAM/GL(8JJ;K)4=AO)F%+/^?\13JK7F;RZ-V]]B+NTB;#
M(H&9/7[8B[1L*J9@;@<#E()YAI]G3-S=8MU:W5(JW%A!6A:.`J.754DRW$Q&
MKLY>Z1MRLIEL^S)$^%29F0SQF)PGU+^:MY6Y(@D92FWJOG$"AXT1AL5CAT$X
MB/=G;3-I=X>\'7[WI]Z'3V>K?:^%>F69\1J%S,\5@'Q)`A?*UK>R>JI`YAAY
M88MVNM_,%;P-JF'-U6,^0?:W7$LQTE"YP^.[CMJK\82-36>O&J,?)V6*IMH5
M.946@B95)J(`42]"CVCI>W3^!K3='K944-0HM+X>+O3R<HGG$MHAJBNHDUS5
M4V.,3EP)^MA$?NY3FJYVN+#(L+1]\F"]N>2:[8U7@U*_,ZO+1U9R(QBCMPDE
M*9>,>VB'BF,@@5TF*S24@TI!N50ASM"D.F8>[;-%Z+U2R7K(^\T\G!29I)0H
MSEQ!0XI'Y6,<VKU%J2R.AJXH;6@XA7#($<AB:WBX\P1M2Y%9",Q79FH[<=R[
MPI$6.*[E/LY*O7UU^["J3%=Y,UB$;&^(FD!SQ;MJQE``3>"DY3246"'ZET)=
M;`#5";]!]ND'`;U#9SQ(K/JF@NJN!R353(8$R"CN$]O)$VF5HC(<_C6]PN)+
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M2Z9RM8Z*B8]PZ6$A%%C)HB5)-502)F[UUT%H^U4#EPJ$/=TTF9DM4Y3`PZ3'
M*H=4W^OK$4;*V^\69":<-^^&G7^WOS!*<`U=1?(3LK=V8S8AWL,_VMO8Z#;O
M.Z4RK=K8VP2;]VV(IU`%31B`F`.OAEZ]`5R:[0G>$*H:OAG('OL>D"7EB:FD
MU0I'SED+Y$2\<X5'SUYB7FIVWYIRE@3)M]PBSO\`B&\6*@VU&,P_2I*,^&:W
M)+QSM>-D$TB%=QKDR(*H*"4AC)'*)BE-U*#3M^@-&W"@:N##;W<.H"AQ.*)Q
MYS$)JM5:@I:A=,ZILNH,L$Y^.-Y;#O-5;JH[<-3XG?4YH%OV\6M\TKMNL-1Q
M\WJUHQF5^X*DC?6"=;*L>QQL.H8#2$>=!595GWS-NBQ"D5\5^^%MJ50*<L@6
MBXHZR05<07_4(WG9*/5;-:UOM247'@4P3(D"13RGSP_S0[W3LGTNKY$Q[98>
MY4:ZP<=9:G:J\^1DH2?@9=LF\C92,?-S'1<M';94IBF`?9Z"`"`AI$/-.4[R
MV'TJ0ZVJ2@1(@[H:#;K;S8>:(4VH3!&(C76XJO[@;-BJ=B=L61*!BW,*SJ*5
MK]PR;1G^1:>T:(2+=68:2%:C)^MNUE9",*HDBL5P((*&`XIG`.FO30+HFZD&
MXH6Y2;4I/"?#C&JJ35.,%-&I"'MA4.(0G3R5\FG/]QM9AI&.<C2^VR[UK+2R
MK+#F1<<86,X@<@R35S'-'U?+$3$XM.05OCW,RT(LP6[Q#E<)G056(83`VM,Z
M<T+J&E6\PBH;6T)N)6YDF1),Y;@90O[Q>-2VFH2VX6U!9(24IP)')TY;8E8#
M&OF2/ZAC9/'='LU_KK^!"6,NW#^HQH+01%F=\>HCE7WR$86VE`"M@3]ZC%F=
MB)?A($0!P,6]HT#[=W'LU1[)Q2[SO/-';[C5GL_?=^WWLI\'#AS3G'=JFXGE
M(`IP2X]-M!E`+U(!^1)<B9C=.H`)O_:*)P+[8]T?L#KB"VV#/O:K_(3^''05
M<+L,F6?\P_@Q^#);C^6I-),8_CHVM**BH`'`>11=QT3[INH]U7:C$D+]\`=O
M?,/[7V0]#=MTVLR74UJ!O+`\RB8^#<KYL8I_\[[$:JR1O+Y;,9TJXY)M6P#:
M-7J50:K.W&T2;_?PJZ+'0=;C'<Q,/CJ)X&8E$B#!H<P$[O41+T`1$>FO8U8M
M,5+B:=%95J<6H)`[@XDX;3&A^Z7IIHO+9I@E`F9N[MW+$&7#]/<@^Z/=)N6Y
MBX?;=@/+TEG9]+8EH,=EC<C+X><XRJ==?0A9*&QY[QPOE)Q+P+&(BXV"))*M
MV)S*,'8""AEEP"9:L:LULM=/I(.U*0S)Q?=-A043D5DJ`XCB3*>0GD(C]C=N
M556NWQ*&B7)I3QK(X1_5P/3E#*YY_?AFIDXQ1G;9+M'8X5R>Q7HF7SQV^:^7
MB8:XVMS=2"N_O"H'V65IC:),E;?N008'EHY%VKT3,\;E,*Q%OW5GH5"KHWJL
M5;9"D<3*4B:3,35QDB9Y(EG>7&J)IWFF2RM)29.$GA(QV`Q5Z<C.RBX<?6[_
M`"YMAMCL\PVITJA)T:U"V.U2N6.+(U),TVQIIF(4@.E8MP#9\1,3)H239RB4
MQ@3[PV9TY>F;Y9VKBB<U"2MI"AVO'ER8PF[S;EVNX.4B\@9CF.7UHDH\N-R"
MI[*M]T)1+[958;!.Z%%ABV\`[=HMX&$O)G9C8LN\B9T=-!J2-FW:T6NOWR%2
M92ZJA^\"0!J.?$6PF[V550R.*LI^NG:9>FG#9*9&XQVM(W/V"Y!AQ4J=Z0(G
MA.?5/08M#2F`P=0$!`0`0$!Z]0'T#JLX.,C@J7GE#F&("AD8\M9@A5CS%=/K
MEYW4<(=3MT*RL-7M.]):IV2#E6Q'D1,U^R7;`4=,P\FS5*9%TRDF!SI*IG`0
M.F8P>@1TTOAZ\NGM]U>:)2XBEX@1GU0LCQRB#:M0ARKH&W/5J?D>DIA(CD]V
M=2.Q#?)GW;@9J^2JM6N#F9QB_>I.`^&,66TI;%0WB3IP'_B*C&$D",'2Y!,4
M7[-<O7O%,`./2]W1>;'3UTYKX`E7(H8&8WD@'IG"YO=`JW7)VG((0%GAYCB/
M+#D/E+M\7]9>WG)FR"W2*RUKV^2:N0L;"]>$4,]Q/?)4Y9F'8(''WQX--O:B
MBIQ[2%2G4"%Z`3II1?%6Q&FN+=Y;3)M_JKEEQIR\7A.$,+0UR[^E7;G3UVSQ
M"9S!V#FAOP?1]7_3I3$\./+$\(F)0H#NM5+RD<LV;:\^3_/39EQ(;=\FSEBC
MCIED*59]UTO3ITZ;9P!>C*1FJ_/M$TO>[@QTTS4MT3L3=*`=KV@G3.FVG!U;
MK=*A`W*#(6)<LB!XQ$#N`3>+TZTJ:[?1LJ.&15PG#G!\D5\P#]GV-6!0%`)"
ML,,O)"I5,1;-\"(#_9"['Q_]-+!^DJ\`&JHZVE_%%;O[X^00\]+S^@:>6?#$
MOOV=18XQ((30\T!<I?=A?-N?&YMUH(97W"5=AD7=7=TX)@C)V&ETNGXSM3IE
M56SENDN[8R%UAV+UX=D84C/%VT0F4#G=MPTW?AJTW:&7]17!9:HE!+*-RUE0
MF3O`GX)[H7^LW%5ZV[32)[RJ3-:@,9#A^M"'U0MEFQU<:Q>*C*OJY<:19(>T
MUN:8G,WD82QUR2;RD/)-5`Z'0>1TDS35(/L&)VZ>+R&ZVF4TX)MNMXC84J&(
M\!A8H<6P_P!X@R<0<-DB(MW.+'?A7>1;9CB[<9&MV\3;7C=S3LL5A%P@L-:R
MC5`196=JF1'H9&,F1.C*QY3E*H$<_1[P=[KJIVI[,YI^\.T"I]UVD$SZR3ET
MC(G;#YLMQ;NE`BJ2?QA`"N<8&)%-<$8B<=6(^N5_LXR]_(]?]DG/'V?5U/!_
M=UW-+R3J"CGLJ4'QQR[Y[FJ/S2O)%/:'MZM[*6$5_P`C%NEPJ`']E%L0#L^;
M[4OM_?O.W52M9#BU/7$_]8^8>:'QIN8L=/+$\$<K>96H&/+?Q'[@Y^ZL(I:=
MQU,XLMF.)5XFB,A#W)SDVJ5@XPZR@E6(XE:Y/OVBI2#]\@L<3`(%[.M\.G7V
M=5,)9)X7"H*ENX3F!NCPZP:979'%N8E$N$G82<@8J]ZC:;%1[56KI491]!VJ
MI3T/9JQ,QBJK>0B9^"DFTK#R3%=$2JI/&,@T343,40,4Y0$.W5EGV67Z=;#D
MU,J2I!!RD0<>82G"<9<4T\AQOUB5`CY0.$77^-)J7LN.:#8I]J9C.SU+JTU-
M,CIBD=G+2D$P?234R0E(*9F[Q<Y!+W2]!#IT#T:IO5(;;JG6FC-M+B@-T@3*
M7)*46'IU+6PA;G;*`3TC'QPD)YRSY9<?GUZSN5_SK@_3J^$*9L5IW*1Y%PN/
MB!ZRFYE_>Q!!P"HJ+<O^R,$R]X27^X+'[0#HFEB>_&.;H/IZ%#T:G6O)?PM6
M<7V@'^-)B+Z6]_4_ROO51;']/8'54@.M(Y3)\4/69F#MF/&90@[MXV1X,Y`>
M<7F?V[9[@325:FHC,\M6[!'F*A9L>W=EFC';:`O51?&*)6DW#"^5+W#@9N[;
M+*MG!%$%E"&>E=>JVQ:*L]PHE=<<$TG)8X%$I/(<^<"%?1T%-==1U]-4CJ$&
M6\'B`!'+YIPMOR%\?&=N-[<)-X)S7&^^FQ@<3.-\C1C5TE4<I4H[DZ#*SUUP
MX)T1<)]`1D8\YCKQKP#)'$Y!2558VG-14.H;<FNI")"7&GTD*VX;HB-UME1:
M:HL/@\,\%2P4GZLQ$UGE^><B1V86J"VA;G[`_E-JU[L3-A1KE,2XF2VYV*:>
MN!<O!]^`<I<63TF\*K)H%43)%.!4?)!T.Z(I"]?:*%U;-VMJ!]((25+2/R@&
M,\/2`Y,<HDFEM2&@=%%5&=&3(3]&?FY-D6.$7*QLW&1\S#2#&6B)9DUDHN5C
M':#Z.DHY\B1RR?L'K4ZK9VS=MU"G353,8AR&`Q1$!ZZKZI"T'@7,.`X@X$<X
MAKH6E:0I!FDC`[#"LWF6DC+9&X?D4R]Y5;?-$I)AV!WCJ3N+RE#J/8`";IZ>
MS3+^'8`I+R=OL*O#)7FPB%ZQGWU`#C^/\XAJ;H/3IU_6]K]32SG@3(<.&'AB
M;R$^/'/[,*)V'B^V*O'Z\B[\O9O>DEW!D2G<(;G,4@=3PFZ:11%NWW["5(I"
M)`7KT[1#K[.F6B\7?(76WRYE?Z$095NHL_H^JG\H?ZD:_?\`%YL';&4`OEXN
M011<P&5332W*455MU,81*0SECOB?%1`.GHZ&$H>QKTIO%Y,IW>W!/R5?Z`C3
M]'40Q%!5^'_Y(A7Y.-L&UJNSV$MJ>U+BDW,[6-X.;+_`JU=IEW,JM]D;/2W#
MB5@`B*?6VF<L@UU%Q-6D4"B_DBMVS=LS7,54I0.HG,M,U%80[=;G7TE1:V4F
M?=HX>MG,DI2<!/GC@WEFFFW0TE,^S6N$8+,YC<!QF4\(F)QKQ;[6X2J5:N7;
MR[&[ZUS\3"QD7-W60W>XS^$K-*LV2"#VP2+6,W7U2#8N9AX0ZZB35NW;("IW
M4R`4``(E77RMJGEOHO-&&U*/".[4))V`]0Y=,X[E-04[3*6E6^H*@,>L,]NT
M#'DB7SC@V);5,29D>9/H'%QG39#?Z?67J$!D#+&<XK(L;/I65):$FZ]$P]3W
M.YD9G=)1JYA%60BVZ94C=4E`5``"'7VXW!ZG[AZNIZEA:A,-IE()QQXD(/@)
MB06JDIVWBZFF<84!Z2I@^`F.%?-/\>K'.VUR*WJT*OK.\N;8BMH^\+L"&.O.
MX"EI!T>8%VW33,=R?'UEDDY-(_4I6\>YD3&ZAT[LG^&&HET-R-G?5PTU09C^
MJN6$LNTF8.$<C6MI]JHA7M)/?,GK;RD_6V172D,)#E.01*8@@8HE$2&*8O:4
MP&#M*("'8(=H:L/))2>*1029SRD1(@\DNF%("4JF)@@SGM$HM<N"'D*0Y!-B
ME*G;&\\7->$"QV',THJ!W%9&=@8AJ:N79,HG,91O>*T"+I4_0"_"2;Q,H=$M
M58UO8%V"]K;1\U=!6C?(G$82$TG#+*4/'3-U3=+8E1/XYN2%#E`P/,1XXFDU
M#XD4+&\_*2BV[K@J(D43G/O]KQ@*`@'7NWK"9C=!-T`.A2B/ITR]"*/T7=TC
M(T?DXHA6J4@U]N!VU'G28T)YL?8NXRQMRQSO4HE=*]N&W:24J>4W;(G1ZXPS
M<71`CY5T4A3&>(TN]&1Z!V"BWF'*IA[A!Z>OX5WWV6XKM#YDR^.-.X+&&'.-
MF.(CS:VMWM%(BXH$W&S)4MRLB<-APYI0F'QJ;SK/L'WGX5W'P#Q=.$KEF90F
M3(M$IU"63$UE=-H[($(HW()1<+C"G,Z9@(_N<@U04[1)TTXM2V5J^65ZWE/7
MEQ(.T*&(///RPOK+<%6NX-U7H`R/-%H=R,;_`"D;+M@V2]X4+(Q=H\2EQ7]2
M)4#IOHF[7K(S1)MC(4A(H0'D$HN_3DG8IF`PQC98Q>T`#59[!87[S?6[204R
M6>.>$DHQ5T@8<\H=%VN;5!:U5X,TJ2.&6TJ[/V8X?XUMH,]M*X=,E*9'`SC.
M^XO$V;]S6=)1R'>DW-VRQ0I.6CHN254(58'U>J1(]J[3ZBF62!T<GN@B/:OM
MU;NNK&@Q\R8=;:;&X((!/.3M\4<VTT*J&P+6Z/TA]"UJ.V923+F&R*N/V?M!
M^MJSJ3.1.X0E5&><6SG`C]$)L>_U:6#])=XU5'6W\TUGYWS"'GI?W%3_`"(D
M?SUFNC;<<+91SSDR0-&4+$='L=]M+I(@*NC15<C7$BLTCVXF(+J4D3(E;M40
M'JLX5(0.TVH_14KU?6-4+`F\\X$CDF<2>:.Q55"*2G74N&33:23Y@(7TX!\'
M7W--KW1\QF?(U-CD[?;;9ICB*#$P+'IV`:[8"L&;5(Y^JZ:$L^JT?'M2G[31
ME>;+@(E=:G>N*QJ@:IM)4F#5&@%PCTG934>@'##;MB,:9I7*E3U]>$GJI1X.
M1(F!AXN:%4_,7\>,ALGWTVC)-5A46&!=UTI8,JXY.P(4C*!N"JK%WE:D*()E
M(BP^#+3,C(,42%*B6,DT$DNHMU>ZU/AUJ$WJS)IW3QUM,`A<O2$\%">,I8'E
MB"ZNM7T?<2\T)4[O6')O'AC:GEF^1MEM`W?NMOF2YI=EA3=LXKM-167.8T=5
M<TMWX,,=V!?O'\-HQL19)>%>J%`H=]RT55,";81#Q_$G3RKK;?;Z<`UE,">4
MMXE4]Y&8CT:-O":"M]D?/XEXR'(HD2Z-^$67P#U^QT`0^P.JY)((F,MG-LAP
MX[<XX,Y3FR;KC3W]I*][NEV>[BEP[IN@]]MBFTN4_8$.GB(AU]L-=O3?\P4G
MYY'ECEWO&T5`V=TOR13N:M\HR!/I3BOXQ.,6$VR?F*L^R[C#VQ_GAQH[[;/B
M[&&"*LU<YUJM,K#S$,O'-&AE!N!;*6PN7,'47[A43%>OVZ!2%,'4OH`:\WG2
MS=UU-4!%QHD/NO'J$J*DX]D@#M>*&Q;+^Y;[0R%4E0IE*.T`)'QPMKRO<X&=
M>5F4KN*0@8';_MJA+2TF(;'WPT\FGDO/$!5@PMV4[>2.:?"?P0@[5,W:,X]!
MHR!4YA*Y5*58&3I71%)I<&M42_<R">(2D,,`@8$3&<R3$2ONHZJ]E-*`&J.>
M`G.9GFHC*42\<07EG6=TD<6[M=W.6L99(PXZ:5W(V+L:8+M3JVP^0#$<H2<4
MXR!=EH:-CDZT@JV[KF*C/?"SL_>17<H`FJBK$=6_$IQ"7+5:6G$U/62I2QPE
M,\Y8\N9&6R.Y8-(<:T5U<M!9"@H!)GQ2Y99<F>&</@D*4A2D*`%*4`*4H```
M``'0```[```]C22^K.<,P2`D!(0B?YRSY9<?G]&=RO\`G7!^GG\(/45O.CR+
MA9_$#UE-S+^]B##R^GTP6RS^F%]_0_D+4VU]CI:K^0#_`(TB(OI;W[3_`"O,
M8M@!U58=H=/DAZ'9\H>40FUQ*]OF2>7;_(V:?TYXOTW-3_\`CNU';U/^VJ%[
MI_\`FVM.V2ONA#%'(UQWX,Y)=O4[A#,,:FRF6R+Z7Q7DYBS16M.*KP=KX3*Q
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M9>&1)$3*%7WS1@D33'O`JI^=6'"HB4I1$#F'Q!`O_6[/3J+?#T_H-XGF*)0R
MVR7XH[6KS^/MXF#^/&.S-,-3][^^]GT?W.FEI(=C8?,/LQ.I"4MD_-">MFJ>
MT:/D#-W^[OS,\:X`I1-[UA]W@MEP,DD8IDC#@91N?PR&`!\+L`W7O??==-%#
MM9MIM._^S^'"_4BC!];=)<ROP8T[:0V05N,E)>P<C?F7JA$P+-W*3DK+M=PT
M7'Q$:S;&=O'LJ^FMO)6D<R9-2&5555,F0B8=XQNZ'77J85<'G4M-46G%NJ4`
M`.[)).```<QC011R*A4788;U?@Q#OLLI%$W0[ILX[F,T9#YF[MC&F2[ZI;8,
M^;>Z[DG,FX5PU8R<BT9L\@9JA*-/,Z[(15#>("XC6#=F85)4Q0\-),Q5IE>'
MU6NV,VZB;M3=2XD*>:<*&VLO1;*@2.(G$\41ZWMM5M2NIJ55RF@9-K2"M1QS
M*^'")LXZC[62@V<+;B/-0$41.43(O87=*)SBF(??J?!^)%D0*J`=>A3ATZ^Q
MJ$..UA$C3Z;&.SN/PHDB6Z2>#UW_`,?UH8\XVL=TFE;>2S6/\F[V,FUK(-NG
MK,V<[])3(#G-E=<1PHU!W")PN2ZU5;36*P=>MB[:-E6@)KBY,Y3.8BX",!OC
MRZBNDXU1M)0F1]GX0@[?0)!.^)=:6T-TW$VM]:%?]:?%XY8;H[LL-?A+7`S-
M7LL4QG:[8HN0@YV%E&R3R-EH>5:*L9*-?M%RF1<LWK-<Z2B9@$IB&$!#IKDL
MN+9<2\T2E:3,2S!&7@CH.-H=;4VOK((D>414'\H^QJX\>^\[+6`Y^)>MJ@$[
M(6_#$ZX((MK7AZPRC]6G2S-SWA(Y7CFZ)XU\'8*<@R7)TZ``C;#2MY;OUH9J
MT*'></"X-RQGAYLI&$/?;8NUW!RF4)-S)2=Z3E'8?E^.0A[L3WXTJ,M-A0B<
M"[BW<7B/,!)1VHVA(963=G3H.0%C&,#5HO4;.\(FNY5#N)13Y[U$.H&+R=?V
M'Z;LBEM)G6TP*TRS,I3'+,3$M\CF)QT-+78VZY!*S)AV23E(;CS@[?#%J&F<
MJA"G(8#D.4#D.40$IBF#J4Q1#L,!BCUZAJL4E`\*A)0SY_L0ZP01-)FG8=_+
M"R7/6^2+O9X'8SJ7Q7&^]B]*7J/?\%G>L#MSB!>G:7OOR@(]?2(:9>A0?HB\
M+&RC\O%$-U/+Z0MP.?M'X,,797QI5<S8PR#B2\QR<K3<F4RS42T1ZJ::A'4%
M:8AW"R28%4*<@*@U>&$AN@B4X`(=H:7=,^[15:*NG)"V5!2?E`_6PEER1+'V
M&ZBF6PX)I6V4RYXIS-Z.UB];*=S^9-LF1$%?A_%=O?PS2241\!.RUAP"<G3[
M<S(!C%!E:*P]:/DR@(^&"_<-T,4P!;FR71B]6MFY,&25I)(W2[0Z#""N5$NW
MUSE*X)<*Y">[9XHGXXC++FWEMO&Q'CVS$B]FMI?'Z^NF?,BN%%W,DGD")BY=
M(V)Z1=B/BFC_`(*AY*3"OQ[8.^<8-V]*0`!(!)`=5LT&EV*R^TA__3KTA"$Y
M%`/;4D;S+&)58G*N^.4]L=QI*>:U'?+LIZ(L!=SI"I;9MP9"%*FFG@S*Q2E*
M`%(0A:%/```4.@%*4H>@.P-(VUDFZL%6,WT?="&?72%$\!V>[5+^Z9Q2P]/1
M]7M:N.B*['.+9O@1^B$V/?ZM+!^DN\:JCK;^::T?^KYA#TTO[BI_DQ#_`.9Q
MWL=^1P3QM5<M\G(/*LI7\N;L&&&84MPRHVPQ7K0T5@ZI7:X+Z.CUY6=<1;R6
M\%ZY;I=Z,9&5.1NL)C2KX<64<+^H:@H0MH%#)69(XR,S/GEA'#UC<"5-VIH*
M5Q$*6$XGA!R/EC:^.O,=;.\(XYH.**1Q\\C%1HF/*G!4FFP2>"*"T:QU>J\8
MUB8QF@"F6R>)X#-L0#F[3&,(F,(B(CK55?#^[5E2NK>K*13[BBHGCG,DSW^+
MHC<QJREIVDM-TSX2E(`'"=D1S\O'+=M!Y.]HT[@\NS7D`J>4JU,M;]A.\SF$
M:,,57+[&-G3'WG/K1^4I"5)4[-$/UV,A[W1742!1-R1%51NF0>_I72MSTY=4
MUJ:JG53KFE:4JE,2/+*:3UN64<J_WFFO%$:;V=\.SFDE)P.W9M$\,H2R17D(
M:11<-U749*1;U-=%5(RK1\P?L5RJ)*)G`2+MG;1RD`@("!B'+[8:=#B&WFBD
MXLE.<L2-O(0<H78XFEX`I<3OS!BUVX->1+^T2V/4^Y6^7C'.>,4K)XMSA'MG
M`&>N9^&:IA7[RY9G'QD$<A5\J3XQ@#P??Y7:28]$1`*K:WL"[#>UM,`BA>ZS
M9EE/-/\`9RELG#OTU=472VI5/\>@2(VX9'?C'4W*)U_LUM_O7_X<;DOT0VW7
M.TY+^(:267?(^ZCVWKW34?F5^2*=;5P`)JD8K\,XMXN(^`B9+BCV/5^78LYF
M&F-J^.6<K&R;5!XPD8^8K"7O^/?,UR*-W;)P@[.DHF<IBJ)B)3`("/6H^JG5
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MG9*>0.W9A%C<7M#ZOLZKX`!@!*&UGCOA$[SEGRRX_/Z,[E?\ZX/T]/A!ZBMY
MT>1<++X@>LIN9?WL08^7T^F"V6_TPOOZ(,A:F^O?Y5K/S8^[3$7TO[]I_E_>
MJBV`U54=H=/DAZ'SCRPFUQ*__I(Y=?\`(^:?TYXOTW-3_P#CNU<R/^VJ%[I_
M^;*[D*_NH<DZ?K!]W2C(!'0(80$NC#HB+/E:XLL,<G^`WM"MZ+"IYCJ39](X
M3S*E'@YF*/85BD5/%2?A&2<R]%L:J!$9./$_3IW7"/<<))'"2:7U+5Z:KN_9
M)52*(#B#D1]L-H(W@@[(XM[LE/>:8MN2#Z1U5;CN^P8JL=S>V;,VS_-MWP!G
MBHO:9D>AR9F,@R7**C"58G'Q(NQUR2*4&TW6IUF)'#-VD(IJI&Z#W3E.0MH;
M7=**\TJ:RC4E3:P)2QY^+<1E+">T&$I6T53;JA5/4)*5I)SVC?\`T1)GB'D<
MS=NIL/%#M2S,*=L+M7WD8K7Q[DU[(2#JWR].M61L<1K"G6L'8N2RAZF$.5%@
M^*H146/AH*$.*0*FC-=IRDM35TN=(.!511JXFQ@E*@A1*AXS++DCL,W:HN"Z
M.BJ9*+3Z)';BH3BUF[.GH'IU^O[7I^QUU5^9SVCS_P!$.[BZG%MX9],?$W_)
M..\3UEW<\HWRF8WJ#!1))]:KY:(2GUQFJX,)&Z3J<L+Z/C$%5S]A"G5`3#Z`
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M\D=W2]=;$V9EAMQ`<2#Q`R"ID[MT,/I*$63(JF<JB:A"G(<AP4(<AP`Q3%,4
M1*8IBCU`0$0$-0;+`X*VC=$LDA0"A(@Q[.@>UKY(!SC.64?/V>V5:E0[BPW&
MRP%3@&ATB.YNS3,=`Q#8ZYP21(XDI1PU9(F65,!2@8X=XP]`[=;$-.O*X&P5
M+/).-;CK;(XG"$I\$(M^;2S+LXR_#;4QQ7EK&^2MP]1GKQ'3:.-;/`W08?$\
MM'LW*C6XRE<D)!I%.26]F@:,:.#`N8JSU0I`+WC"ZOA127BE=J14M.MV]:4J
M3QCAFO(R!SZN[FA;:XJ*"I0UW"T+JDE0)!G)(&7-N&^$K`$0$!`1`0$!`0](
M=![!#M#M#V-.HI21)4N';S;87`,C,9Q9(\'/.CMJSCM@QG@3=%G"M8JW,8>K
MD90G\MF:V0]6BLQ0<(FHQK-MKMQGW;"*D[$>#;-V\HR<KDD3O4CKE*JFKWPK
MCK71=RM]T<K;?3N.V]XE0"`3P$XD$#*><\L8<&F]24=31-TU8XENJ;$NLH`$
M<YVQ&]SW\D.V:3Y+.+UY1\FP.4:;LQRK'9;S9,XRE(^Y144$YDO%,ZI"1\O$
M.UXB5L<56,=K.%FR"YA1%VFFH)51,0LCT)8+DC3MQ#[*VGZIK@0%@I)D#*4\
M93PW1R-3W6F7=:0M.)4AE<R4D$`S$\MLH<WP_N4V^[@(F)FL*9JQ?E)C-0C>
MQ,"TB\UVQ/AAW)$#D>.8N-D'$FP!(7!"+%723.@J;PU`*?J72=J:&NH'%,UC
M2VUI)!X@0)[90P*>LHZI(-,ZE:2`0!*<I0G#YNC8^@4N$]_5,AU/'552P1FM
M=DU5.0R?A/9G%EHDCI%,D@5+N2,0LX5[O>$S!$!$>Z&F_P#"F]D%ZQO*'"!W
MC<\I$]=(GLE(RVF9SB!:ZMA(1=$#$]5?1D>?QQ+/Y:C8F.TC8#!Y0N=93ALR
M[K'S?*EE6>,U6\_'8Y*V.TQ/5G_O@A%D$4H19>9\$2D,DM-J%.`F*`A%/B)?
M1=[^IEE7Z+3IX1\OTO!'=T?;$T%L%0X!W[W6.\#8!YXDVY`MQ>!<1[5]S[+)
M>9L9T>5)@3*30D)8[O78JQ.7\Y0)IK!Q["ONI!.9?R4TZ>(ILVZ"!UG2BI"I
ME,)@#4:LE#6U%RIS3LN+1WZ"2D$B7$)G=AOCK7.KI6:5U+KJ$DMJ$C*>*3%.
MQZ.O4?0/W?U=6]`D/2P.T2/BA`[<(LA>,;E2V1[.N$+;W<,EYUQ\]MV(\=W"
M#DL+0-PKKC,DW>&U\MC]A28>@KR2$\,G*I2;50KA5$C%%JX!RJL5`#'"N&H]
M,WNZZSJ&F*=T-.O`\?`2A*3+K%7)C,0W;->K?;]/M..NMEQ"#U)R43C@!R;X
MYW\O_O!VW[H-R^_O>[N.R'BRE[P<PY/B8:AUB_W."B9NF[>$8)K\`57&R]C>
M1AI6.;+,$(V3.Q3%8P1#51<I`7+W^EKRTW.U6ZAM%O;=5:FVU%:D),E.S&*M
MTYX3WR&4>32];0UM747"L6!7+5)(5+!')#B#%ZRDV;20CG35_'OFR#QD^9+H
MNV;QJY3!5NZ:N4#*(N&ZZ1@,10AA*<H@("(#I4JXTF2IA7DB?IX2D2Q$?EV.
MS5JH1+B<MD_!UB$;&2(YF+#*Q\+%-SKJ%10(O(2;AJT2.NL8"$`QP$QA``[1
MUA*'7#P-)4I9V#/G\\?#O<H3Q.\(3A.<M\5A7F2,3[:\?\B$I=]LUVQC8X7-
M]$B\EY&KF,;#"3\?4<INI:7B[0O(?F\\>QT:\NI&"$PH@(D5,Z=+K&(`*E$U
ME/AO77%^PA-P;<"F%<*"H2)2=O*`=L)K5[-(W=.\I%)*%B9`R!C27!SR2(\;
MF]&!NM[E)M';WE*--CO.,9%>*\19Q#I7QZW?30Z93F?O*#.=UP/A%%T,<N\2
M1`QU0(;W:XTX=06DML<"K@UUD$]J>U/2/'&C3%X^B;@''5$4R^JOFV'PP_\`
M\G.\;:E(\8F\N7BMQN%)ICD/:EF.N48T'DVGS3BVSM\QW-5ZIQ5?81<NZ?2S
MZ9EYENDFF@F<Q>^)C@4I3""#TU:KFG45*RNG?"DOIG-)'"`<9GZ\-"\5U&NT
M/D.M]9I7".(`XC=%35JV,SGMA&9&7+%LYPT[C=O=UXYMD=/I>9<93-JK^!,9
MT*=I[.[0!K9$WBN5IG&6*MR%95D"SK68:2;57]Q.@!E"=%$P,D<AAJ?J^WU[
M.H:QUYIP-J=4I*N'JJ0HS"@=@W\W)#RTY5TJ[73H:<25I;DH3Q"H]O-'QP0'
M(_LSNM$BX2*6SWCEC(WO;U97102>Q]R8I(.I&H@^*`'2A\C1D?\`!;DA^\@1
M<[=R8HF;)B&='ZA5IV[IJ"O]`<4$N)V<,Y3EEAF(^]16I-VMY0@#VA()1AD>
M3GBIYG(2PTRR2U>GXV4K-JJTT^B)>(D$'$9,0,]"OE&;]@\;+`FY82,:_;F3
M.0P`=-0@@/00U:AM;=0P'&BE3:TC&4P0H3ES$0CW$+9=+:YAQ!D=\Q%E'P2\
MV.)MVFVJNX@W+9<K5*W384AHRKV24RA<J]7#9KKS?QFL!D&N/IM[&_#5@(P;
MI-I]N'?<D?$]]&ZINR]VN&N='5=GN:ZJ@9<<M;QFGA$^`[4G=O'(8;^F]0T]
M;2)IZIP(K4C&<L0`)&?-A$*'FZLYX;RQD_916\891H>19FBTW.3VX-*/:H:U
M%K:-MF<8)5TLNX@WCYJQ<RIJL_%-%0Y5NXW$XE`IB":;_">FJJ:EJWGVG&VU
MK2!-.<DJQQY_#$;UW4T[[S`96%%*53ECM&Z(0>$K,6.<#<H^T3)^6;+"TV@0
MMXGXV>MEDDF4/7ZY^=5!ME4C9::EI%5!C&1;66FD/'<+*$313$3"8``1U--:
M4S]7IJJ8IDK<>*)I"9S(24DB0S.&`WQ&M..H8O+#KA`2%YG(3!$SR"+2*R;W
M=FU1KZUILFZ_;C#5]NR4D3RK[-F.$F9V2:9EA6;*?G&;WX!DB")2I`<Y_04!
M$=5A;L]V>>[EJF?*YRP0J:3EUMVZ'4Y<[<VCC4^TEL8D\4YRW#EA)_AQY`]M
M;[G?WSYZNN0(+%N-]U$?FUMB6S9"EHZK03YP\RQ4;96F$U-33IA'04E9*I6U
MW#=-P<@&<`#8#"L9,IW'J_3]T3H2AH6FU+JJ<(*THFJ75E/?F9$"%[8+I1#4
M=35.$(:>)X>7'/RP^S3[S2L@Q9IRAW"K7:%(X%F>7J-@BK)%E=E00=&;&?P[
MMXU!<&SM)3N"?O>&H4W3H8HBD'6G65%#R5)5/)0D89K3K3PXF5!2)[(^J$`'
ML$`$/K]NM9Q$CE'V0#F(ALYA^(;%G*+A8&R8PU$W*8\9/76&\N'8%$X&[BSA
M3'MW5:E![(T&?=F`3=/$6BW1@=-R&'QD7$NTGJRKTS63"BNVN$=XW/\`Q`'`
M'EPYXCU_L+%X9X@$IK1@%':.?.*W[;5AS)6W[D]VQX8S!4I6C9)QUO5V_P!;
MMM9F4#(.X^299EIH=Y,W:D\CGR!B+M'20G;NVRJ:R1SIG*8;#W*OIKEINHK:
M-8<IG*1X@C\VJ%%34KU%>6:=X2=2\@'^\(N$^SI]7M=-5*&1Z//#_D.*6R?B
MPA?+S+_T:ZWJE]>^+O7%\0>X6?XG_G#^P_)/?&ICH3W\/7>K/JNUG$>U-[K_
M`"6?Y3*$!ZU^*+?1V_C0_*3\:]S#W+\G_P"UIX+_`'IE"O/9/S&/KV'X^R^C
M#_&V_P"-?BWNI/QC\G_9_M>NM+GJE>].R>UE]7V8V4_K4_,LQEG%L_C+U=4/
M\2^1E7^+/BSXC8_%OY!^\_P?35;*OYV[GZQ6>>>V')2>H3EV1EET1]SKSQZ8
MA8Y^_HV<D>HKU@XF^<9ZK?EHP^-/Y3_B7Y1W=231?\QM^NS_`"?;Z(XNHO=J
MO5_V\H09_P"3MI\>E^ULX5?^QC/_`"=-;/\`EXQ_Q\8'_@Z_:U\K_>\'^PZ(
M`_X.OV]"/WO&?]ATQ/SY<GY]]K^8%\WJ\?-A]8?RNQ]^._S8_C'\/X&H%\0?
M<WZ[ZT>NRRB4Z5^?J^;=G\GGLAE'F:^C7W.^I[Y.U3UZ^KCU@5+XU_E'_%_Y
M=X6E[IGWXSZS;ZO.)9>_=B^QGZ>4225?Y-5_XJ^)(GX@^(OQ!#XD_DG^+?P7
M=UPW_G+GRU=K/ICJ4_S9&66S**Z3S$GTJ6:_FL_(W#/K*^67JMJ_QO\`M?XO
M^3>%ITZ%]P-_/NTKU79SV0M]3^]5_-\AVL\H@_\`]Q_4ZV?M6(]_LH/]Q_7R
M?WK!_LH!]'^Q!Z?8]/H'T?=^MK4]E^T^SMC[;[?ZGT1;![!/F-;./B3YKF!/
MDU\GO5;5?B/^2/XM_`=S5;+E[Q>S]8KM=K,Y^?EAPT'S%K+L[(X<Y[?HV<K>
MH[Y8XJ^<3ZK?E[#_`!S^6?Q+\J[FNWH_W\WZW)7J^UV%9>?DG'.U#[M7ZOT>
MWV>T,_JSE"!9?9^AU](^GT?X/UM/1GL?M;HA6*[1^8=,9]D/H=?M?5Z=;%]G
M]KQ\[?U"/']C]#I^$/U?9UJ:_>O3&\]C]2CS]G_Z==;O^7C3M_4([ZXL_I#]
MHGT77KGK7JB]9GH<_(W^6_WGZ_74;U/[F?\`>/J3V^SEZ7)OCL63Y^CYIVQV
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MQ3^I#UL;;_DMZZ?G#4OUS_S9_P#*_P#!>_\`3AT7_*%P];\W=S]5ZM78Y?/"
C[U)_,=)V/7#+M=H9P[__`-W[/W?3^OI-?D?JY88WI]$?_]D_
`
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g302169logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g302169logo.jpg
M_]C_X``02D9)1@`!`@``9`!D``#_[``11'5C:WD``0`$````9```_^X`#D%D
M;V)E`&3``````?_;`(0``0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!`0$!
M`0$!`0$!`0$!`0$!`0("`@("`@("`@("`P,#`P,#`P,#`P$!`0$!`0$"`0$"
M`@(!`@(#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#`P,#
M`P,#`P,#`P,#_\``$0@`1@%:`P$1``(1`0,1`?_$`.X```$$`@,!`0``````
M``````H`"`D+`0(%!@<$`P$``@$%`0$`````````````!P@``0(%!@D#!!``
M``4#`P("!04'"@\,"P```0(#!`41!@<`$@@A"3$305$B%`IAH3(5%G&!D;$C
M)!?10M)#MB<W=Q@XP8*2LC.S-"4F=I>W>#D:\.%C<U1TE-2U5BE9M%5UU99'
MA]<H&2H1``$"!`0#`P<'!0P(!04```$"`P`1!`4A,1(&05$'82(3<8&1H;$R
M%,'10B,5%@CP4K(S<^%R@L+24Y,D5#4V%V)CPS1$=)0FDJ)#@U:C9-0E-__:
M``P#`0`"$0,1`#\`/XU(D+4B0M2)"U(D<>[<M6R#ER\71:-FR2R[ATY4(@W;
M(($,JLNNLL8B22"*1#&.<P@4I2B(C35#XJTE-*)ODREGCEE[(N\4-#6H@-@3
M))EZS`7?>\[VK#(["Z.'7#N[%%[1466A\S9QMYTJD2XBMU0]ZL#'$BB8N^)!
M=,"2LJF:CD`%!L8""=065Z7]+'T!O<E^&E:0/#00,)YD@\<I#"4*MU9ZJI>+
MFV]NJ"AJ/BK$^&4B.$Y^7.)P^R-SC_EK\-;87NN8))9JPDHSQ7E?S%2B_E5(
MQH4;1O-RD(`<Y;I@$BG44Z[GJ+D/$!`!7U-VFWMC=CJJ<'X1\:DG&0YCEGCY
M"(*72+=@W/M5MNJ5_7J<Z2.)`]T_(?)$R.A_!5A:D2%J1(6I$A:D2%J1(6I$
MA:D2%J1(6I$A:D2%J1(6I$A:D2%J1(6I$A:D2%J1(6I$A:D2%J1(6I$A:D2%
MJ1(6I$A:D2%J1(6I$A:D2%J1(6I$A:D2%J1(6I$A:D2%J1(6I$A:D2%J1(6I
M$A:D2(C>][&1SOML<E7S_*UT8E-"V_'R4?)6S)N(X;MEQE6K*+QS,IM!2>RL
M%>SMX5HNU243$PG`QC;"&*.Z],EN'?--3LT[;Z2H:M0)`XSP/#Y90/.J2D(V
M55/U%0Y3)0#I+9`*CP29@Y_)%:PH4I3%`B?EHA[)$Z[@3$I2%,4!J(`)1"@@
M`!Z-/N$%9^L`0G+0GW1'/M+KCE+K22:D$ZE<2/HY^>):^RSS?/PDYK6=(W%+
M"QPYFE1CBK+*:QS`P8-I=\0+1O1<!,!`5M&?5**AJ;B1[AQ0:#30KZK[;8W!
M8%MLH'Q].E3C:ABI1`GI/8H"7G@L]'-S_=V_H+RY4SZTMK!,DA*C(J$N(G/&
M+*5%QYQ2G3%,Z9R@=)0AP4363/U(HF<HT,4Y1`P>B@AUTE*DE*])X9\P>(\T
M/7XB5-!QL@A7N\B.?GCZ`U;Y8O\`+G"&OH"OWZ:M45CW`#%1+C&-WK"GSZL#
MA!DL2B2Y0MWR#\VK]:.?MCSU'D86[Y/G#]75-1S2)IBX$'/`P@,`C2@_?U1+
MFI4I$1=AS$;:](I"U(D:B:@@%*UU:=<^Z)B*X2Q($8W_`"?.'XM6^()R((BA
M(`P()C.[Y!^;5VM'/VQ9J/(QMJ[/$91?"U(D8&M!IU&@T#Y=3#CE%%3"3IQ5
M*--YJ=``1J%?OZL;7K)"L)11>M(!D)G.-PJ(=0H/^_J\RX91>93PC.I%(6I$
MC7=\@_-JW6CG[8LU'D86[Y!^;4UHY^V)J/(QC=Z@'5"XD98Q4$G`"4+=\GX1
M`/Z.J:UGW4F+B4C,B-]>D2%J1(P(T"NH2!B<HH<!&-WR#\VK=:.?MBW4>1A;
MOD'YM36CG[8FH\C"W?(/S:FM'/VQ-1Y&%N^0?FU-:.?MB:CR,+=\@_-J:T<_
M;$U'D8R`U"NK@0<1E%PQ$9U(K"U(D:;A]0:FI'.+=78?5"W>L-4*D#C$U'@#
MZHSN^0?FU36CG[8IJ/(QG<'K_'JZ*ZDPMP>O\>I$U)C&XOK_`!ZI,")K3SC4
M54R^)J>'H'T@(^KPH&K5+2A.M6"8J2``3DHX0)QWK\@W/SCYK\7>TSAV4,,:
MZNZ$R%GMZP$ZH1Z[ALM),D9#8(E!*Q[#(]ESD.(%]Z>MRC0Q0#1WZ;6ZFVUM
MBMW_`%HTN:2&)S[QQP&$^\H``G"0A>.J5?5[JW/1]/+:2IK4E;^GZ,R!,DR&
M`.(SQB$/O9=O.,X'<H&0XSAUXW`&98)*Y,9)&4470@9J$:LXR]+-,Z6$YU'#
M1V5)^B!CB8S=\``'L#HO]*MYU6\+4ZW5*"KRV1K3*1TF>D\$XR(D#P@+]6]F
MJV9>A\(T1:'VP$*PD2GWL`21(D3G+,2B&@0W@)3"(DI0P@IMH4`J&U0OT=H=
M0$/#T:)#`;45*K/=2<9^SC`F*:BE4E23I<.(E%C9V*N<0\PN&=OP%WS`2&9>
M/I(W%^0!7$"OYB&9L@"P[P5+6JHS=O(%17.%?SQJK4>H52WJIME[;>YU^"V1
M;JI1<2>&.8SYX^?E#W=(-VM;FVVV'W-5?2#PR#.<A@#V\O,.,38$$#%`0Z@(
M5`?6`^`]=#<B1E!;F#B,HP<1``H%:C3[G0>NO)Q3B0"V)F>/DB=SZ9D(:?S"
MYBX=X08K3S-G%:[6]DJW/"VF"MGVN^N^3++S8.#LC&B8X?>",R`S/YJWT2!X
M^.LY9++57]_X:@2A3\IR)">,LSAG&`OM\8L+'Q585)IN8!5ZAC$7X?$C=L@=
MW^%69@$A_+.4V()PIR'Z^R8AG`'*;H/00T0!T8WNI"G$-4ZD(5I)#@,E8X8>
M0P/5=;=CH5H7\2E6G5(H(PYXJ[80?$B]LL3;0NG,@^B@X?FQ,(^D.KBFKQT0
MW\M>AMIKQ?S0X/E$O7%G^>&Q9:UJ<2P9=XH)S\BB8ERXT<D,3\L,/6=GK"T\
MO/X\OAJ]5B';UHK'2;9Q'/UXR2C)>+5W*QDK'2#4Z2R)Q$Q1`!K00$1K?+5<
M=NW!=LNX\.I;,BG`X\)$8$03;%=[7N"@1<K2==.L8*Q'J./+A#@!$`UC2H!.
MHY1EQB9#.,"<H=!'\>K@"1,910$&<OHYQX7R0Y"XMXLX<O//.9)U6!QU84>B
M]G'C-HI(2BQW3Q"/81\/&)&(M*2K]\Z3210)[1S#7P`1#[[59[K?+DW:[2G7
M5N3DG#&0F3,X``1B;M>+39[>N[71>BC;S5C+$RR&)QB(`?B1NV46E;IS+0.@
MUP_.`8!]0T7'K7Y=$AOHOOM2BT66_&'`K'R"4#5WK;L9I:4)6M;9$P4H.7,3
M4#&Q?B1^V0=0B1+IS2HLH.U-%+#L\JLH/J(BFL94WW@U:[T:WJPI*7FJ=*EC
M";@Q]453UMV.M10GXDJ!D9()]BHEIXO<FL8<N\-VSGC#ZURK6#=R\PA#FNN`
M>VQ-"I`RSJ%?^\PK[\Z:D%XR.*8F&ATQ`P!UT.;I;:JSUKM!6@!]I12J1!&!
MS!&8Y03[7=*6[T;5;23\)U`4`001,3D>T<<3#B1,`!41Z?<'6/3WO=C[U*"!
M-4<=(RL=&,G[Z0>M6+..8N9!\[>+D:M&3)JBHNY=O'2PD1:M6Z*9CJ*',!2$
M*(B(`&J,*2^^&&YER8$@#F>`PQ)X`9Q1XJ:IU5`]T))!,@,!/C#%.&'<<XV\
MZ+DSE:^#+B>2DC@^[B6_+&DFZ;-*ZH1SYS>/O^T/RQU9*S).28NFR+@Q2&WH
M`)BE*JD)MKW+LZ];5;IW+PPIE%2C4@S!!'E23ZY1J6UMXVK=#U0Q0/(<<IU:
M5@3!!XY@8>2</[*8#%`0\!K]WH(AUKUJ`ZU02X91N)&DRC;58IE'@_)/D)CO
MBMAF]L^964N!.P,>L&LE<!K7@GERSA4'LFQB$180;'\Z?J>\OR5*00VD`3"%
M`'7V4-!5W*I3242-=0HX"8'K)`PCX:^Y45LIC5UR]#"1.<B?8"8B$#XD7ME;
MU$QNC-1%$J>:DKAV>252J)@#S$E%B*$J)1I4`KHDT_1S>E6VIVF;IUMIS(<&
M'J@6/];MCTQ2*CXE&K*:#C_YHR'Q(O;)$:!=69A_^D,W_P!8UZ?Y+[YP'@L]
M[+ZP?-%J^N.Q&TZEJ?"9_F_)KC]U/B.NVRFV!X,QG@&HD*H1T?!]U%:'3,7>
M4Y70T;B0Y.H&W;1#TZ^5/2;=:G2S*F#B3(CQ1@3YH^I76':G@I>0BJT+$TDM
MJD1YE&.T6?\`$,=KJ[G!$5\QW?:9%!`OO=V8KO-JP0$:?V9S%QDN!`Z^D-65
MG1[J'3*THI0N>6AQI0_2$7L]9.G3TDU%5X;O)3;H/J29Q)[@SEGQHY+QYI'`
MN<,;Y422(!W#6T[E8/9=F6@C5_`G41FV`T*/19NF(4UI5SL%ZLRBBZ4[K2AF
M2,)_OA-/KC>;3N6P7P3M-4T]R`,CZ%`'U0X(JJ9Q$"FJ(>(4'I^$-88*23I!
MQE&?*%`3(PAGG,WG!@W@CCZ`REGQQ>36TKDN]M94:M9EJ2%WOPFW,5*RQ!>1
MT<`+-8\K2)5JX,.PIQ*40J(:S5DL5QW!7?9]M2E3X$SJ4$I2GF23EB!A,XQK
M]_W':MMV\W&YJ4&=6D!*5*4I7(`<<SB0,,XC3+\2-VR#%$P75F:A3;3?O038
M"0U*[3E%P!B&IZ!`!UO[/1G>U0Q\4PU3K8GF'!\TX';O6_8S#WP[QJ$O<B@C
M^-&2_$B]LDPT+=69A'^*&;^Y_P`H]>O5GHGORH44-,,E0$S]8![0(M<ZY;#:
M3K<4^$G_`$#\BX_=M\1UVU7I!493F=7R0!45F6$[F>(A2H"!EFYE$BF*("`@
M(U`0$/$-?,GI!O!3A:":7Q$SF"\D99YRRCZ_\XMH^&'=%7X9E(^&HYY?2XQ\
M_P#M(O;*!0Z0W1FHJJ751(^'9Y-1,*5$3IG6*<H!7K4.@]!ZZO1T;WHXH);;
MIE*()$G4G`9Y1XN=:]DM?K15)QEBVH8G`9JC/^TB]LF@C]JLS=/']Z";_P"L
M:O'1??)5I#+.K]^/FCR7URV&A00M3X4?]$_RX?[PL[D'%/GTSO!QQWOF0E).
MPG#1.Y[3NJ$<VK=S!E(%_,)U*"?F,N^@'RA3HE=I"9,BR8D/M,(5U'=.R=R;
M.4C[>IBTRY[BP0I"O(4DD>10!,C*8QC>]M;RV_NM)%F>"GTB:FR"%)\L\#,2
M/=4<")R.$/R*H0P@!3`(B43`'7J4!VB(5\0`=:IPGPC:8_!Z[28,W;Y??Y#)
MJX=K>643G\IND=9380OM'/L(-`#J(ZN0DK6$)]XD#TQ8XL-H+BO=2"?1C$"[
MGXC_`+9S!^XCGMRYK;/FRSENJBOANXD%0.U<G;K`5)98AS)`H6H&V_1$!$=%
M%CH_O.J']613K'8XF!,]UEVA38U**I`EQ0?Y4:'^))[8R90.>[,S`4QBD*8<
M03E#'/\`1(4?/]HXU\`ZUZ:O5T:WLVG4XTPD#FX!\D>#?7#8KJ_#;-0I?(()
M_C1]O^T;=MK_`-;9[_R&W7^IKS_RAWA^;2Y?SJ8^G_.39_YM5G+]6<__`!1/
M%[7J'\`?JZ%>MS\T>G]R"SI7^>/1"]KU#^`/U=36Y^:/3^Y$TK_/'HC`@80'
MH(?[ODKKS<4]H.A(U>7M\D44DD=]7=XX1X9R5SO9W&+!&4\^7\N"%JXPLR8N
MAX3S`(K(.F3<20\"RW![<C<$PL@S;A0:JK%UF+-;*R^79BV4R)K<5(_*?(!,
MQA+[<Z.QV:HNE4N3+:)IGSX`3_*4X'8^'RP7>68+QY&]TG.[-1[D;D#>MSVQ
MCE])(*"+:$4F!>WU-Q)ETP.5DO(MVD&S.0"@#6+5(`[3"&BWU=NSM#;Z/8MJ
M&AFF8070,!J`D-7:,3ZX#?2"UMW&HJ]^7A1565CRDM$S)"29F1[9CTQ*IW>.
M$:'.+AG?N/X:-2<96L8BF3<.O_*`7!+UMEFLH-OE5#\H1M>,.*\:H`4*)EDQ
M'Z`:T?IYNNKVSN%BL)**99"'1PE,2,NR9\DS&]=2-J4NY=L/TRDE=<VE2FSQ
M!EC(\)R'H$5F[A-PW=KH.VJK%XW65;OF+I(4UVCYNH=%VU<H'*04W#=P0Q5"
M"`4.`A33UMU-.])\R\%U$QZ(Y^/TU13N+8?GXK:]..>?JB4;L\<VU.#W-.Q;
MNGY55EB/**K/%.8414-[HWMV;?)%@+L<(A4IU;+GU"./,I4C518/`=:#U+VD
MG=&TG7F0#=&`5(YR&,O.)CSP3>D^[5;9W2RAQ1%M>4$K'"9P]LCYHLQVJJ2[
M9!=!9-R@NDFL@X2.55)=%4H*)+)J$$2*$53,!@$*@(#TTCNA;<VUSUI)!GGA
MSA_$N(=2'6Y:%`$2RD1'[C3I7TCT_`(ZF,0Z<`>)PCB9&-CI9$6LFP:2+;<5
M4&[]FV?-]Z==J@(.DU$@4`!$`&E0KJB&W&CJIW"A79'@\IIR;%2T%H&.(!!]
M,!J_$R\=,9Q60^&]WV%:5KV5>V6IF\\?71+PD,QAF\XDB\M$MMOK@1BD&Y'K
MB'=S2I?/$@J@@<P5&@!IFN@U[N`I+E2W!U3U,R/$FHDR`)YSA8>NECMQJ+:_
M;VD,OU0*"$@"?NRF!AY8%;R;CJZ\0Y&OC%E\QRD1>>.[JF[.N:.4`P&:S4`_
M6CWNS<`&%NL=+S4C?KTCE-X#IBZ2Z4URH&[C;3J#R`4D<Y3/M$+9<**HM=>N
MV5X(\%1!!Y<(*(^&,YFC:5_9,X27E)[8._T765L/)O%@*DTO&*:D2OVV&8G,
M!$QG85%"11(7Z:C-<0J8PZ73KMM%#H;W&PG%$D/?PC@?3/S0QG0;>:FWG=NO
MF:5@K;[-`Q\D\I<Y0:P!MY?"E>H?*'H'IZ!TL+N!\,0UC:M20YSC0XB4!,%!
MH'I](UKT^7575.>!-KW\/FB@$W@1[JA`C'Q"^<+QY$98QWV[<-.2N?L)9%V\
MG,_*IJJ!&QS&R;4EKEMV/G10*=0C6&@HYR_.`^R+IXS+]*FF&Z-VRFM%.K=5
MUD"MQ++4^:N(_?*P\P,+?UMN-9>GV]I6.:E-I+KX'!'$&7(8RYP&BF8BB:"A
M.OG)D4(-*![8`8!H(C3H.FH#FE++_P!,'4K]Z09>LB%'6I:7EIQDVHCS`R^:
M"^OA9\4XXNJ-Y>Y!N2S+:N&\;?N#%5JPT_-P["4>Q4+*0]T2TFSC%7K=8S$K
M]XU1,KY8E$_E%KI9^OUQKF*R@IV'5H86VHD`D3EHE.1[8:;\/EHH*ZCKZNX,
MH<="TZ2H`RGJG*?D&,&(Q\<PCD0;1S1JQ:IU`C5HV2:H)`8PF.":*`)I$`Q^
MHT#J/C72VFH74`H=45.C`DXS,,XS2-4N+0"4'(``2'+#"/K,82F`H?>Z>CI7
M7BT%>)+Z`!]>4?2M*U)FV0#/&<!F_$@<WN4EEY/:\.(>2A<?X$O;'T->\D]M
M":=FO3*<9(/GT8_M^]G0%:*6Y;[.4C#E^KFPF"1(!#*K'3$40:+H=L^P72W.
M;BJTAVL:>TI"@)`B7NC(DSSSX80KG7;>6YK57IL-M=#=&Y3DJ*9SD9SY=O9Q
MB`_ML\SIK@CRTQQF]F=V:QRNRV=EN":&$J4UBR?611G$B-""5)9];YDR23.H
M"(.&H%+0#4T4M\[:^]&VJBSK0#5-@K:61BF6(2#PG*7D,H!_3W=E3MC=5/=5
MK/PZU!+B9GO!7=)(XYS[)3YQ:$VG<D#>5L6_=UK2K2<MJYX>/G[?F6"Q5V4I
M#2[5-_&/VJQ1$%$'3-<ARCZATBS[#],\NFJ4Z:AM12H<B#*.A=-4L5E.BKIE
M:F'$A23S!$XYXWH^[U^Y37F,)F/18)D!Q,<8_CF<BBJV>H-G;5<"^>U=-T7*
M*Q"B42E427(=,X%$`$`$!"H:L:<J&9O-D@GM,Q'G4L4M4CX9]*5=A`/J,"/?
M%'XCQQ!8RXJY)@K+MF$O=]DF[[.?W%#0D=%2,E;1[5++I1<BX8MT#O6[20:`
MJD"F[RS&-MI40TP?0.X7-ZXU=NJ7E+82V%2),@=4L!PG/'R0M'XAK;;*.T45
M;2,(;<4M0F$@8`)(R`YF`V5"&VK$*(!1-2H_THTIZ0TU=7H>IDH;P<"3C"G!
MQ)TN.`E94/)%H#VU+0M*9[>7#D9>UK;E/>N/&.1=^_V_$/!=F/;[<B@N/>6:
MGFF4#Z0FJ)A&HUJ.N?>\'[C3[OK4A]20E\XZC/5PX^2.B^S*2VU&RZ!YRG:6
MDTXP*$D\>8AK?<8[*'%WEWC6ZYW%^.;5PSR-CHI])V5>]AQ#.V8VXYQLD=RV
MMZ_H&*1;0\U$S2R0(&=&1!XU%3>16@"0VQ[-ZDW[;MV;=N#SE3;P1J"E%1ES
M$^(S(XQKF[^EM@W)9G$T#*&+J9E)``Q[99=A]45[,!<.1\*7^>7MB:NC&V3[
M&GG3`\Q:TP^@9ZWYV"D'#-\T2?LUVSA+W)XU.0Z1A,D-!`Q1`1`70>I;9>[8
M$U],VXAYL*'=!EK`/$=L)6BMNNWKD?@WUMNL+*3B1,I,N&<Y<<8/=[%_=6N7
MG58%UX>SJZ8..1N'HR,DG-P-6Z,<7)]A.E_JQM=BS!$I6[2Y(F1`K:3*E1)4
MRB2Y2E!0P`G_`%3V"QM*I;N%J2K[-J%2(E[BYF21V$"8Y2EE*'$Z1]1ZC>-,
M[;[JL?:#`FDCZ29"9.6()[<#CCA$]4I#1<P@5"6CV$HV!0JP-9!BU?MP4`HD
M`X).DE4]X`>FZGAH2H\9IU;U.M25J3IP)&4OFR@P/4M/5MML53:7$)5KD0".
M//RP!K\3'B^P+`YIXDEK(M*`M1W?^`VDW=OV>BV40A-S,9>ER1C>5>MF"+=!
M:1%@0B1U1+O.5,NX1IIN>@-975NVZE%:ZIQ++H`GCAIGQX3)ERA/?Q`6^BMN
MY654326RMO&0`$\IR`@>FTHYM+W9:42[(!V4M=5LQ3Y.H_E6<E.,6+M+[BC=
M<Q?O]-&2XOJ^SJFJIU:%I:.(\D!6R$.7>GI:@:D%X"1QXQ;1V+B#%MC6G;]J
MVGCRR(&VX2%C(R+B8RUH9JV:,FC)!)!(A$V8;Q*4M1,?<<YA$1$1$=<[JZLN
M%76.U54^XMU2E2.HSQ/:>S#D,(Z1T%IMU/;V6*:F9"-"9]T8R&>6)\L04?$8
M\?,.O>W]<N7$L>VI'9)QMD'&[BV+OAH&*BI]NUN2Y&]M3D0O)L6R#EU$R<<_
M-YB"AC$\PA3>(:*G16Z7)>\$6M;SA8-.M1!49$R)$APREA`BZWV&UM[.=N3#
M+;;X>0G4E(&!,B3(#+"`G\U\6<NX$MC"5]7Y`*$L'D-CB&R7BR]8Y%9>WYQA
M)LA=2-N*NS`4C&[+;.&QVT4$#"10BJ8G3-N!J:/=-NO56[::`@UM,K2L<9R!
M]$N,*3?=IWBP6YBZU:%?!5`FE7"4Y3]/HCB>-O([+7$K,UGYUPI<;BVK\LUZ
M5=,3'6-%3\0N)?KBT+H8D,4DG;4XV#RG*`@-#`"B8@H4I@]+M8+?NZUN6V[I
M!0H'03FDCB.(D>46V'<%SVK=&KG;7C-)&H`GO##,<<,,>&$63G;E[AF(NX;@
M]EDVPW#>#O:`(TA<LXP=/DW$YC^[5$O,.F8O15]:\S05HM^`>6Y1J4:*IJ$*
MCV\-G5^S+HNWOS71E1+;F,E#ERU#B/1A#\;-WE:MY6Q%=2J`N`1]8W/%,L"9
M<B>/;(]LA(5,4P'*'6I1"E2F"E/`?$!UJ66,;@1,2AEG,'A+QUY58.R!CK)>
M+[,=*2=K30P%U-+?BF%TVC<*#!9>'N&W[@:-4)*.>QLBFFM0BA4U0*)%`,0Q
MBCLNV]S7BT7-EZWON!"EB8*CI()`Q3.4^W.-0W+M>R76SOIK:=O6EI1!2D`@
M@&4B`(%W^&:XAXDR;.\C<^Y4M&VK^NO$D[:F,;`1N&*9SD7;;Z082,[<MRQT
M7(I+M"2[I(K5!NL8AC()%."8AN'1OZY;DNK%+:[?2NEMYUO6X4DB:2$R$Q(\
M3YH`O0C;%M?J[E<JIE+C#:]+84`9$%4SC@<`/.3!E/V#LC_N;;'C_P!W87Z'
M_0_'2W_&W+^>7[\O>.7IAE?LRS_V5KW9_JT_-G`E=SRG:0"YKD"3[T/-R*D@
MN":"1BVF8<FI-(Q_]9NO?(YJDGC\Z:;9BYW))E*8Q2D(``(AUT<66=Z^"C1M
MZUJ1I$B6&YD2P)[V9@$/O[)#ZPO<-Q2O69CQ%2!GD,>$<']:]H+_`,[#G'_E
MDRA_]O=>G@[W_P#CMK_H&OY4>7Q&QO\`Y'<?Z17SQ@TIV@Q`0#O8\Y`'QK^F
M;)Q?`:^)L>@7T>G4#&^58)V[:Y_L&_Y405.QTF?WBN)_]Q7SQ%7W'+\XQ2$K
MB+$'%3GKR5Y!X]O5ZU=9GN[.&5+RN?&UK,U)U@T@B_9V2@XA=[)0Y".91R;R
M%@*DBD"8;S!0H=/+;>F*2JO5VM%MHZ]M)#0;:2VM1XXB><#K?MSM+SM-8;5=
MKC56Q2IN^(XI:$^8GYN(RQB2^SXCLR6-:\!:-M]Y+F';<);\>DQ80EJ9+R';
M]N1YAW*NPA8-CCH&L6T</5E%02)7:*@@(B-1T/*RIZA5M:NOJ+#;UU2R9J6R
MVI9'^DHJF3S)C>J1CI_24C5$U>[DEAJ12E#BDMA7$H2#(#E#W.#V/^WSE?DC
M8:''3NF\S<]Y'Q\]+D]+&%S9?O9[:MPQ-I.VHR#>Z8V;L^)8RL$*CM--PU%8
M#*E/0`$*TU+<3FXZ&W*5=+);*:G7-(6EE"5`JPU)()(4.!X&-OVTUMFXW9(H
M+S=*BH3WRE;JB%)3B09G$$<(@\^(&X-CQ:Y<+YELR&*RQ#RA/(WI'D:-RHQ]
MNY2;G0-D*W4J)E212E5%TYALD%!HY<`4*)CHS=']QJOUC-MJU>)5T9"<3,Z#
M[N?8#Z#`+ZV[4%DW$+K0H\.W58U``2`4)SP&6/M$0)`4ATU2*5$#D$FVI?:`
M0&H#NZ!6GCZ-&N4D%`]TB1',<O)`4;6I"PM)DI)F#R/.+$7L&<Z%>6O#N,QU
M>,P=[F+C4:-QS=1GJX*25P6.5J?]'=WG`QS*K&<P[<6#A2@_G+$PB-3Z2KK%
MM=6WMRJJZ5I*+;6G6D)$@DRDOL&I0*I#F<H?#HMNM.X=I(I*IQ3EQI`4J4I6
MI2@5$IF3C)*2$X\`(G7I4>H5](5]`^'XAT)FPH3U$YP6C(J!EV^>-J``=``.
MFKM(!U`8Q<23G`F_Q,XB6Z>W+2@".9+H\?\`VQC@?N>(=:]-,5T,0CX&\F0F
M6V@>T%+A(\Y`)\D+WUP`%19%_3%1@>7NPRKXEWAN.-<[6%S!M"+.A:>>&3>T
M,BJMVQ0:L,J6M'$"+DW(E(`H'NNU6A`$3#^57CS^(F'6Q=#=R"MH7-MOKD_3
M*4XV2<2E4L!R"2)2[8T7KWM@4=0SN2G;3X=2TE"Y"7?3,E1EQ5JQ/9V0.GA+
M,-XX`S'C/.&/G9V=YXNO&$O2$4(80*Y6AWI7#N,<!6BC*88&6:+D-[)DES`(
M4'1IO=F9W#:7K4^D*34(5.8G)0'=5Y03,&`3MN\55@NC5TIW5(4RM.*3*:2<
M1Y"!B.,6KG'/-]G<D,&XMSK83DCJU<HV5"7=%@10%3L1DFA#OXAR8/HOH>0!
M5LN4:"55(P"'37/F\6VHLUYJ;95`^(PLB9SEP]4CYXZ.V&Z,7JRT]SIB/#>;
M!D.!R/KC[,[Y@M#C]AO)F;+\?%86CC"S9N\II4ZGE^:WB&:BZ$>D/ZYU*NRI
MMD2_KEEBAZ=4L]N?O-RI[=23UU+R4#_1F1,RY#$GLCTO5SI[!:WKU5'ZBE:4
MHC*9D9#RDD`=L"M]O[$5[9>X=]T/ND9M9'5R3RUQ?GV+Q][XEM4B,:14#.?6
M?U:=0H^1'R$DT1C&XIB!19PY/$#Z..\+I2VR_6;95ODFDHWV?$"<$K<P(4KF
M0"<3/A`&VC;*NNM%YWU<)_$US+OA*.)0V"9I!X##+C`<3:ON[40&E$6]`#H`
M533Z`&FH<86`5J5W2A(EPE(2'DA1%NZ5NIEBLJ$^/O3^2#0_A2``,><TZ!3=
MD'#HC\H_9B\0J/RT#2M?B#`^T;9V-*]C<-I^'%:S:KF"20EUB79,/3EY9"?D
M$%O`4H!T``KU'IXC\NE^"4I)*0`28911U8'$1UN[[E@;+MR>O*Z)-M#6U:D)
M+7)<,L\5*@TC86$9*2,D_<JG$I"I-&C<YQ$1`*!JYEEZHJFZ2F25//'2)9S,
M@/68\:E]FFI7*BI(%.VG4HG@$@DP#.^XB99[U$=W#NXL"\S'*V^]/;7#NTE`
M,FWNB'Q@5-^^MWREVY@,DO9C4K=/96L])K";Z`Z::@W-;>E]39]J)2V"ZM!J
M%X)D5J`"SV@\\@(4E[;-?U17>-Z/+<%(PAQ-.G$A7AI)TC&4O)SR,#0[%DRG
M!4%$3@H=-PW63\I9!=,2%6;K)&`#IJH*!M,0P5*<!#3$>(EYHU+*ILN9\CY8
M76J;<IZOX=Q.EY!E/B/)!QWPV_/93*N%ICA9D&:,M?V"VPSF+%GK@3NI_#C]
M[M6AT3K&$RSBP)ASY!2`(B1@Y;@``1(:*+UMV@NW79.Y*1(31U)&H`2`4!I!
ME+Z4L^<N<.!T,WFFZVP[5JUJ^,I@2A1.)225'/E/"7"<%%%$#"/M;J=*5K3H
M'CZA$!^?0)U`DIAAI``)XB-MI:UH%?73KJZ9E+A%FA&K7(:^<"H_%4^SQVXH
MB'00S==0@(>@1L1<*_=T=OP^8[CK)_S'\>%W_$6`K;U$#EXJOT4P$DM4=X^L
MAZCZ_9TV*Y!.'YIA0-6E'A_1!3(<!.<S%I'VPZE[>?#(.@4X[XU$0-X!_>)O
MN$?14`US\WXUXN[:\:4E7Q)S$\,/R$=&MA*;&S[8<A\,<NR4/7GYZ'MJ*E;D
MGGS6(@X"*>S<U*O5B(-(Z*BT%7KYXZ6.8I$6S9L@8YC&$"@!>NM>:;J*BH11
M4HU/K(``Q,S@)#MC9G'*:GIEW&I)0V@&9/(14PY_O2.R/GK->18(J98:_LM9
M%O"'%%,J:0Q4_=4M),#D3*&PA56;DIZ!T#=KHI:Z:JH+;3MI)4L4[8/80A(,
M<U[]44]9>ZFHG_5U5#A`'(K41\D3M?#)V#><USQO6_HUHZ"S+!P1=#&ZY,2N
M",225X34`SMF),J4ONZSUP=@NX*D8=Q4D!/2@5T%>N]P+=@8MK\O'<?2M/.0
M!!@S?AXMZWMTO7!L'X5MI23R,_R],'P;0V$*(`/0OXPKI3P2%%(Y0YAP)4G"
M6$`N_%*``<PN.0```'\G!?PZ?_,2Y=-%T#6M%AN(02!XR/T84;\0O?OU$58G
MP3\D#<X__A#L,/1]NK,Z>CI<\5H^71*4LU+21)HTQ,N&1X0OUD)^U*-SZ9?&
M/',1;O1O5FV_YJV_]'2USEJ"0IPC\]4=-FB?#0.&A/RQ"+\1"`?_`*N,RA3I
M]M\.?YQ8C15Z*`'J)3%0G-I4^T2,"'KB2CIV\$8#XIL>;4([!Q=XF8>YI]F_
MBA@O--O%E;;G^.MA+Q4PU(BG<5EW(WB!")NRU9%0ACQDS%JC4I@]A9,3)*%,
MF<P:^.^7VOVSU`KKG:WE-J342(2HI"DR!*3+@8R]IVS;MV].*2U7,)4E5/W5
M$3*5=X`C\LO-`,G//@KF7@%GB6PYE=D+Z)>F>2F-,BL62C>VLEV>13:WEXQ0
M#F39S33<1*1CQ,"S-R/3<D8AC-ALK>5KWI;&JBATHJ4H[[<Q/4,YRSGGVSG"
M=;VV95[%N#M%4(\2E!&AR685B#,\IR\T=2X<<P<S\'\XVWG/"\U[G+QRB;&Z
M;7D%%@M?(-HN5DSREJ74Q243!RR=I^VW6Z+,G(%72$#%&OT;HVQ9]W6QZVW%
M"$*2DJ298H7D%IY'&4^1(XQC]F;RN.S+LFZ4146\E"9DM,P2E6<Q@#+F`>$6
M4O!WFQASG?@FWLUX@E@(5<J49?%ER#U!2Y<<WF1`BDC:EQMTSB8BJ8CYC1R!
M01?-3$63$0$P%1?<^VZ_;EP7;ZX*3I)+:L0'$\%?.)X>B'ZVKN>AW=;6[Q;E
M`I4D>(B8[BI8B0[9PZ^?]J"G"FZE&(DP$!\!`6#BH#\@ZQ%&3\2U^_1&<?`-
M(Z#B"A<X%H^%@]O$G-@#>UNSW:=:]:_X&O/'^I#\&CUU[:;:N5O\-(2!3JR[
M/#EZ)X0!/P_K4NW7(J))\=!\Y+DSYY8P5G^I7[_K^[I?)F&#F?5$!\S=O=-)
M,2Y8[M%<+9./+*2)6$DZS59*3J19`\6!H_<I'MPQTG+QOM44*(B)3F$!T5&Z
M'99;25[AK$JTB8^'<P,L1[W"!([4;V#J@C;MN4C49$NHQ'/*.-^U_=9_\GWA
M-_ENL>OX/LWJ[X38:3I<W'7!1Y4SA_V@BSXC?,I_=NW?TJ/FCH.4L_=R+"^.
M[SRQD?M/<';6L/'EO2-V79<#O--H&2BX2(;&=O7!4T;7,LY<[2;$44P,HLJ8
MI"`)C``_31V+9]XJV[90;@KW*EY82D!A:,<_>*R!EC,>C./BK;YNZTT3MRK=
MOV]FG922I6M*I#+(`3G.6?&(8>VS9?-WD+R/S%W+\8\)L/\`(9I=]P7=:</!
M9"OB$QI8%DSLH$:J_;V;`OXY8LRC:UKBWB$E?(!)'<<?[,)A`I;XK=J6VS4V
MRJJ[5#"FDI)>2VI:B`)2.E0./.?"!CLBCW3<KU4;RI;53U#:U*'@J6E"`23B
M)@C#@)1.[]K>ZKUIV?\`A,!:B(".;+'$WC6HE"VRF$1$:Z$8I-AI<#9W)7Z3
MD?AG3/M_607Q4;Y4WK^[=NGR\=L']&'X\'_Y2T\YON6Y.\,L"<5YB(&':V$\
MQ+<]O7F_NEA))OS7&65>Q,5'KPZ3)5NV`B>\P./-$1^AK6-R-VEDH:L]RJ*Y
MA6K7K0IN4I:2`HGM]$;/MG[9J`XY>+936]].G06R%SG/4"0!PEZ3RCY.Z5PH
M8<Z.'63</I-V@Y`BFP7[B"362`%(W(UKMW#J*;I+T,HBVN-L9:+<[?VEV(B`
M[0U[["W(K:>XV*]$_@U*"71/-*C(J\J<QAP/.//J+M=O>&UGK>H`5S:"MI4I
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M.ABC4-(XXTMIU3;DPX@Z5).8(YP_=/4H?0%-XM+`6E4\"DY2],<EJTY1[P)M
M\3.&ZZ>W*/A3,=U?]KXY#3$]#3*@O'[QG]!V%ZZZ'34V5'_W'\F)X^XAQ,B>
M;'$#+^`7:3<EP3UM_7F/91<I!-#9&M@@2UGR*2AZ^[D/)HE:KG"@^[.50\!T
M'=HW]>VMS4UR23X(<DX`931,3'R^:"GO/;Z=R[3?MJ@/%\'4V2)]\)/#/L\\
M5;LM$2]NS,Y;L^P<Q%P6])RL#/1CDAT743-PSQ>.DXUT0Q2&3<M7[91,Q!#Q
M*.N@5%6-U-(:^FD67$A2",AV>>.>-RI3;W_@:A)#S:Y*!X]OF@Q'X8OF<,C;
M>4.$-W21??;:4?9>PRD[<&3\V!DW;='(5L,1.)MY(B850DR)E`1*F]<"`;0Z
M*UUVVREIRGW-2ID'.Z\)92.!)\\LN4-5^'_=*JAI_;=2O%`U-3/9B`/-/S0X
MOOO96NW/^1.,/:APQ('&^^2E[0-TY949*J",%CJ,DU!ATYGW?>HWCA79O)A8
MIZ`*,6G7H:NL;TDHJ.U4ERWU=DCX*BIU)8&6IQ293!RF"H#`$YY1L/5:X5-X
M?M^PZ$GXJJ?2IZ6,D!4Q,#L&K$@2B6SD7BRT,']M7->(+`8)1EEXTXEW]9UN
M,DDP3`L9!XWDF22R@!T,Y>"F*RQ_$ZJAC#U'0NMM0_==Y4==5*G4.5Z5J.>:
M\!CR&'F@AWRA:M&QZJW4P`99HBA,A+`)D3YS,^>*MMMU;-C>`>4AT_I":Z"O
MA;P#R520``1SPYQSLJ%MI):T_6:E&?G/"#1?A2?X/.:7\8.'OW,WCI6?Q!_W
MC;?V2O8W#8?AP_NNZ?M:?V/P6R=7RTSG$H^P41$/6`!6OW*!I?"LR49>[[(9
M96!';`Z??^Y-W6KC_$7;NP49:4SKS3NV&MF3BXU0XO8S&!IMHQ<$>@D`J(,[
MNG-K=0_A]7LWIC>R&B]TJM%*IQ[=]S(3;:!*5)!'OJ,S@<@4@<C[W9`5ZM7J
ML?99V5:/]_KU*2L@S*4"0$P,PK4>6">V)E.(W&RT^)7&S$?'FRBHFA\9VDSB
M7CT$0!6>N%;=(W-<3D2[3*.IRX73AR8PU&AP#P`-#C<5Y<OUXJ;B\07'G9MC
M\P?1\LN,I>:"1MO;[.W+'2V=L3IV6CKD/?4<2?3Z8`Y[\/!LO$3F3-WO9\6#
M##/)-64R39Q6R`)Q4#>BKDJN1[/0.F4B#=-"6=%DFR)0$?=G@@``"8U;?H]N
M9Z_;9^SWY&XTI"2"N96,#JE*8]>(,)YUHVH+#NKXVG"O@:GO3"2`B>&G,S(E
MCEF(C4XE\EKWX@\B,6\AK"57&<QU<+5\]B2KJ)-[CM=T/NEV6H]!(P`JUGH=
M99'VJ[%!(<`J76^[LLK&X[+4V2HTZUHFA6>@@`RD,3W@<01G`ZVM?G]M[@I[
MK2S'AN#7C+6)^3`:2,#/G%IM@W,%CY_Q/C_-.-Y1*8LG)MIP]X6Z^3$@G,QE
MFI%A9NP)4$Y"*7WM7"8B)DETCD'J&D"K[>_::YZVU0E4-.$'MD<QV2E+LE'1
MBU7"GN]O9NE*H%EYL&0,Y$C*?,8B/6=?)&1@4_XJK^;MQ2_CMNK]PJ^CQ^'O
M_$=9^P_CPNOXBO\`#]%^U5^BF`EC"7V@..TH%.(F\:`(>-/DIIKW0``I9D@@
MB?*$Z>2=0*<5&6$&X\7^>G<QPCPEX^)63VLYC*^++2PE:"-J9%M[,$7*OKGM
MN/M],S.YW%EQ$>[N!H$@W)YAFR::JQ`&G72C7W:.UKONJL\>^LL/K?Q0IDX'
M##47$@RPAT]O[OW/:-GT`I;&\^VVP9+\60(XF0;)Y\>$06\[^^!S)YI6M<&'
MYEO;^!<5R2JD?=V.+`0EDIVYTFBPE6MV]KJF52SAV*3E$"NF"";)-0Y-BQ3E
M`2B8=H](ML;=*;L\365H$T*P2%'@4CO`'R3@)[SZQ[OO>NV)1\+1S.I`))`Y
M$X$CR^6.#[97;&Q1W"KQ&V'',RS<=W'$M!F9O$C.RYU;*[V#;'*F_=6RK<01
M%IR:+8Q@!59JH^,W*8#*(E`0'5V^>H-SV=2%#=`X\VL?K`X$I;GD"-*B9?P0
M>!CXNGW3FAWE4RJ;@VR\#/06RHN3Q.GOI`\\_)!Z_#7A)@3@SB5OB/`=NJQ,
M2JZ++7/<DJY^L[OOFXSH$17N*ZYLQ$CR+U1(NU),I2-VR="))D*'52]Q;FNV
MZ:Q-;<'M83/2."1.>D8\\SQASMK;3M.TJ;X:VM!!(`6<)K($@HX88<,9<X=T
M)-H!Z@$`#[FX/Q:P!'?+G,1LPP21VP"Y\4K_`#P^.7^C@O\`YQ+ETT'07^XK
MC^W1^C"D?B#_`+^HOV)^2!N,?_PB6)_CU9O[IXK1_NWNU'_*GV&%]LG]XT?[
M<>T1;O1O]QMO^:MO[0EKG)4^\Y^_5'39KW$_LT_+$(_Q$/\`JN<R?X\8<_SB
MP^BET8G]_P"GEGX*_P!$P(>NG_\`.WO^::_2$.][47^K<X4_Z/EA?-&AK4MZ
M!7WJKPLS^O,_/*-TV,$_="W`Y^`/:8[SSEX/8:Y[X-G\+Y@C0)Y@GEK$O:/;
MI#=&-[Q1;G28W-;KM4:A2OENV@B"#UL8R2@=0,7X]L;DN.SKLBXV]1\(J`4B
M<@I/$'Y#+`\\0?;=^UK9NZUKMM:@>*`2E<IE)S'E[1.*U[F-P\S'P=S;<>#<
MU0WNTO'G5?6M=#!LJ6V<B6AYITHR\+6=J``*M'@%HNU'\JQ=^8BH`"4!,[^V
M-S6W>=K374Z=+Q'UB=0)2!G/`<98=L(/NS;5QVE>%V^I!#*530LI("IY#ED<
MY\([QP!YZ9?[?><(O,&+UUY6WY,S.*RIC5Z\4;V_DBSTW!5#QSU$=R+*XHJI
MEHN1`OF-'%2B)D5%2&KO79-HWC8_!=(%8V/JW`,4X92X]HF`8R6Q-^W+9-Y\
M1@G[.<(\1J>"N9G+#L,ODBR-XX<JL/\`,KCQ&9WPI<"4W:5U6])>>R5.D2<M
M:>0CUBRUIW3'%.96)N"&<B*:R1PH8-JB8G2.0XH]=;+5[;O*+?<04NAY*02)
M`@3D1V&7F.</19-PT.Y;$NY6TA22ASNS!(/*8@?OX6$@DQ+S5K^NSQ:1P^X:
MS7NC%UX<+U;;G2-(53+(XX?5P&_P\N>):[DJ4OKF_P#:05A^QTOWS0Q/S0(S
M<MS=MX+DN('W?YYEPSXL],@]AVF7KB3:Q#L))S[U%M4RX\4*FVCE]R*90,8`
M(0`J/CI@:=K=RV4>%MJW+3I&,@2<,S];F<X6^H7L'QUZ]P7-*]9F!.0,\A]5
MER[(X/[4]M'K_P#T&<SZA2M<Q7((@`B`>C'7K'7T-C>+9(.UK<I$L>X#+S^(
M0/3'R.4^QG7$N-;ENB`#*1X\>+0B+/N=9?PJTM6PL6\7.Y;RBY@0N0WCHV6!
MRME69D,56]!,G;$D`QDV2L%`+2$FXFA%V<HE612;M=VT34#1"Z=VR\+>=NMP
MLU#2+:U%LX)*C(C`ZI2QD)&>?"-'ZB7&TH\&VVF\UE73KTAT2U!(G/O22.6/
M:0,X?[A>WNU?B;&5IV+;??3Y)8];QD:DZE[7Q=D"=M.Q6ET22:;JYUK?A&^.
M:-F3N;,NH03F.H8A@$QA'J.D7:HWU=KB[5+VY1N*"R`7$S)2"93FX)X<L(W*
MUT&P;70MLB_UB-38)#>040)CW%9'G'IIKK[:"9#G-\0=S/3*D`G,8V9+B$"%
M(&XQC!^CH>@`'7PUBG&MWH47/NS0C3[W<FD<Y=_`><Q]S3&QG1X9W#<3J/=Q
MD3R^ACZ!!*?"7'$!C3CU9<=:F><H<E;5N1!2^[9R]ERX?M/=URP%X@G-11AE
M3,H]4\6BT<%]U(=$AR)FH(:#M^JWJJZ.?$4R*9Y.!0@23/'R_E*#AM:AI:*U
MH^#J7:EA>(4LXR]`AV"I:IGH`UVG$*?2`1*/4M?3ZM850)20#(D9QLFH([Y$
MP,9<Y17]?$/\%!XV\I&W(FQXDK7$W*!=],R*31N8C.VLQQR*:UW1YA*&Q)*[
M6I@ED`&E5O>@#H4--KT;W>J\V+[&=6%5E(0!C,E/`YF?$'R0F?739K=IO8O]
M*)4M5,D2P"N/DX>F!ZS%*(&*J2H?2$A@`-]2@'@;TB4?'U:/9>04^.4S$M!3
M+$S&)EY_5"^":2E32A,X3GECZHL&?A[.=/\`*>XGCA.^9GWS,'%]*+LYZJ]7
MW2%RXO>)'^P%R&\Q4RKA6,1;JQ+LXA4JC1,QA_*A5+.KVSU;;OZJYA)^SJLZ
M@H`Z0LB93JRU'$RSP,/7T9W<WN/;R;>\I/VE1)T:=0*E(F`%Z<](,DZI2Q`@
M@/<40J!@$/6`A30C40D35@(,LB#(C&!.?B9NET=N:OIS)=/SRV.A#\(==,-T
M-<;^!NXU"9;:(QX!#DSY!,3/"8A>.N^%79E'W0_B>7NYP5ZF4@E`W@<I"T&O
MA5,"U_!I>'A@K29$X>0B<,(T?JFY@E(0//%?S\1/PP/QYY@)9YM&+]VQGRF;
MNKF7]V1VM(C+,"F@C>\8;8'EIFGV:K:63#TJ*./&@Z<#H=NLWFQ?=^H(^)I9
M$#BI`X@9D"6)X<90EO73:*+/N#[:921350,^06>!.0/(<<(B`XA\B[GXE\DL
M.\A[1,X/)XWO&/E'\<@J!`N&UEQ.QNVVCB*B:?ESD$Y6;^V(%!0Y##T)711W
M59:&_P!BJ;0]I(>20DS$DG@9\)&1@5[6OM7MN]T]U9F"PL$C'$3Y<9B#$>RI
M8UU<Q>4O*GNXY=BUVRV0KKG,4\=XM_1P:V[+CRLVTPI'K!N(*,/!M6,*14@[
M3N"OQ`1W#57>J=6SMNR473:W.)4&I.NN)((43,Z3+#MEV"&OZ5TE1N:\5?4>
MYH4E3I\-I!!$L`"H`]AE,1./SN_F5<L*`(?_`(]9;`:^FEDS`!X^.A9M<$[D
MMYD?]Z;_`$A!5WD?^V+@#D*97K$XJDVG]R-?^*0_K":Z'`@TVD9X>R.;53WJ
ME6G'$P:)\*3_``><TODR!AZO_P`,WCI6?Q!I4+C;9@_JE>QN&S_#@0+9<P3B
M7*?U>//T3$^4Q!6=Z7A;=@6A=-\W=)MX:U[-@)>Y[BEG:A4F\=#03!>2DG:I
MSB4-K=HW,:E:B-`#J.@#3T[E95(I6$E;[J@D)`))GV#&&+K*EFCIG*I]02PT
MDK*B0`)">9P@('AWW&>']_\`<RS[W%^;>6$[%=19%;/XJ6`[M>Z+I<6_:RZ"
M\.PG%26_%RK6.7BK21,GM,*9E'\JY5+]$!%I+YL?<-#L:FV5MAIIQ][OU"B0
MG3()*<21[RIS'(2A5=M;TL%QWM6;SW*ZZVA@I2PA(*IXJ!P`)[HE(C#&"`2_
M$`]J4I`3#DR>A0H%<:9,H-.E.MK;NNA$CI!U`\/4:5K6,/>2,>8&K+M@R'JY
ML4K)^)J)#O?JU2,L9>[F>6<1K=USN.=I_GWQ%O'$\-R.9IY4MI8F0<,RCW&N
M0T"L[[@&Z_EQ"[YQ;)2MHV[8U=:-7]LI0%<AS=$PIO73O9_4#9&YVKH[2I72
MJ&E:0L$2((F9$Y'GV\XT7J-O/8V]=KNT;3SJ:Q'>1J;4"2)&6(X@<)F8$!:!
MN.FFL8I:;25`ATS)]2D$2^:E4A@]L*F\1KUZCIGW$O:DUCR0'9XI&(QY9\\>
MV%"4I/B*:1JTJR)!!P[#+B(+U^&>YY%BY*[.!.19H"-I(TQDCC^X>K@""3L/
MSW(=@-!.<PD\X*S+%`M""(.REZ@6JS]<]J>#4)W+0MJ+2I!W2DD(&GWED>Z)
MB4S(3($X:;\/V\E/AW:]>ZE*D(U-!:@"HZ@-"09:C(SD)F22909(0X"0!$Q?
M`.H"%/U-+@EQ"TZT*!0>(.$-%QT_2'"!4_BJOYNW%+^.VZ?W"KZ/?X>_\1UG
M[#^/"Z?B*4#M^BQ'ZU7Z*8"25Z@J`^`IGI_4CIJ:I16`P0=$CC*%"6E.E+J2
M"K5(B<6D7;%*!NWAPSK7<'';&U!"NX-L"VH)1\0.`>`^.N?^]F`-UU[;9(4'
ME`'@/+YXZ/;#>4O9UN<4$DE@$CL&<O-`I_Q&7;Q+A?+S+FGC&`(VQIF^71A\
MJL(EIL9VIE\6QO=ITS<A")(,LBQ[4YS']DH2S<XFZK@`L1T6WLY=K9]U;HXD
M7*G_`%1)`U)X`3Q)$I>B%IZX[#<MER.YK:D&VOCZP`>X>,Y8`',><0.GB'*]
M]X+RA8N8L83B]LY!QW<K"Z;8F6^X?(DF"H&4;.TDS%%W&2B&YL[0,.QPV4,0
MU2C31KO%IHK_`&QZV524ZGD%,R/=,I3@$V"]UUBN;%RIE*^I6%2Y@&<HL].W
MKS:L#GIQGM#.UGF:Q4RL3Z@R99@.04=6+D6*;HA<4"L4YA5&/.L<'+!8P`#A
MDLF;Z6\"H;NC:]5M*[NVJH2H)!*D*(("T3]Y)E(C@93`,="MG;KIMW69NZLJ
M1K,DK2")I7(8$3F)B1$Y8'SP^`QBB4!`Q1`1+00$.O4/#6MZDG`$$QMA!ED8
M!:^*5_GA\<_]'!?_`#B7+IHN@B5*L-P(!(+R/T84;\0BDB_48)`(9/R0-QC_
M`/A#L/\`QZLW]T\5H^W8CPZA7T?ACCPR,+]9<+E1@YA\>T1;NQH@#-M40_N5
MM_:$M<XZG!3D_P`Y4=-FB-",?H(^6(2/B(.O:YS+3K2^,.5IZ/WQ8?Q]7CHJ
M]%4J<Z@4V@%4V%Y8_1,"#KH1_EV__P`VU^D(=[VH?]6YPJ_T?;#_`.S0UJ>]
MP4[LKTJP5X^7HC==BJ2O:-N4@@@,C+'B8D%]?0W0:5H/4!](>N@CK5'$)=2!
M.-M7)"@L8SSE#`>XAV^</]PG!LAB[(+8D'><41U)XMRBR9$5GK`N@Z0%2<D&
MJ:DC;\CY94Y&/,<$W*(5#:J1,Y=KV?NZY[4N@JJ=1-)(!Q$\%IF)]@/(^8X1
MIN\]FVG>=`JCJD!%9[S;DI$+E+SB1,QYQVUM7*'C%F/A[FB[,&9OMI6W;RM=
MP8R#E'SEH&[H!8ZH1-XVC)*D)];6Y,H);TE``%$C@9)4I54S!IX;%N&@W-:6
M[Y:EI^%D-2`1J!Y$9@CB(0S=.TKCM6[+M%Q2?'"L%RDDC@0<C.8AR_;<[CF4
M^WGEI_<UO^]W9B2_&J<)E[%)GYV[.Y(\S55NVN2`47'W:.O:"!7\T<&*!5B5
M;K""1JDP6]]D6O=]`TMS2U<45$TKPY]O`X3R\L;%T_WY=-HUBD-J*K<XA8*3
MEB1+S\08),^%;6*YQ#S1<)@8$7&=+.<(%/3>5%Q9+M=(BFT1)O(10"CM$0Z=
M!'02Z_4ZJ2X6ZF4H*T4RP".7U<H/7X>%H=M-Q=0))4XT9<C]9."M/V.EY^:&
M)^:/'UL"X)74565PKB5==50ZJRBF-[-,JLJH<3J****PHB<ZAQ$3&$1$1&HZ
M^]N^75GN-UM6/(M8]D8U5DLM0K4NDI]4\RR@GUI,-DY77CPGX;X9NO-V9\9X
M8@[9MR.75C(\V/;#"=O*X1`R<3:5JQIH@CF2FYAV)4T@3*8J8&$Z@D(43:SE
MB8W5?+@FBHJBO<U$:E!2B$`GZ4O/*>>48+<;FU+#:EUM>U0`)!TH6V@*5(?1
M$AAS(R@3KLM6W#=P#NN9;Y)9@M:QDV%GV==F5(C%J4+#!:L:ZN1^VL2S(".M
M=)BG%NHVRK;DE`.J9(YCN$RJ']LP#IC.ISU?LSIY1V>B=>*G]*7')DK&:CWL
MP21*?FA=>E;%JWGOVKOKS33;3!4I#02`E<^[[DI$">J4I83@UPN`L!&ZAA/$
M!N@=0QG9@].H>/U((=!#2M_;UY.5=6_TBX:C[%LHP-'3S_8I_DQL/'S`ABCN
MPCB,Y3`/LCC6RP+00\!I!A[(AZZZM1>+XT2I%;6*"C,CQ%#TY'TQ8NQ6-V7B
M4=)AD2VB?LPCU2+C6$0S0C8MDTC8UDBBV81[!!!HR9-$$RI(-6C1L1-NU;()
MD`I"$*4I2@``&OB*G''%/.ZBXK,DSC(M-M,H#;(2&QD$B0'HCD##0IAH(T`1
MH`5$>GH#50)F1CU`F91'MW0N+UH\M^$^<<7W*FW;2D?9\O?UBSS@I/\`!J^[
M'C7<_;\J"J@@1%$ZK4[5Q4=HMG"@#K:-@W:JL.YZ=5`9)<=2E0YA:@DCRY1I
M74&Q6Z][:J17RFVTI23Q!`)_+]R*N<#BJ0AQ`"[TR#0!`2]2!]$2B(;1]%!$
M*>`ZZ`I,T)(XI!]($<YW4!IY;8Q"5D>LQ(#VRN9\EP2Y>8YS:HY>'L)=P>RL
MO1#8PA]:XRN1P@WF'!6I3@5V\MI<$I1!,?VUL-!]H0'3=_;98W/MI^E<$ZEI
M/B-'DX,`?02".1,;_P!-MV.[5W*U4(F*=Z3:^6DD$SY8@8]@BSPLV\K9R#:L
M!>=G3<?<EJW5#,IVW9^'=)/HF9B)%%-TQ?L7:(BDLFY;*`8``=P=0&@@.D*J
MV*JB<735C1#R%E)21B,<B(Z"T=535;2*VG=2MEQ`(D1*!)/B<<DP#/,7`"S5
MWZ97EN7!<N19M(!(<8^WW%VV/$Q[]<04H0KHT2[VUZ"5$PZ8?HC2K18KU5>&
M2I38:1AF9$R'JA=^N=32JO%GHE.@A+FI<CEBG$^N"]HR1:2<>SD6*I'+%\S:
MO&;E$Q3INVCINDNV<(G*82G2614*8H^DH@.EVKFE(6IA>#B5$$<B"0?7#%4;
MH>9:6T9LJ:2H'A(B8B-CNX<-TN:7"3*N/8E@BZR7:,>MD[$:PE`')+XL]HY?
M)1+=?:<Z873%BYC3E"A3&<E$>A=;KT[W2K:VY*:M!`:4?"<_>+(!/F'RQI'4
MG:;.Z]M5%/F^V@K1^^0"0//\@BMFQ9BV\\QY3L/#=CQ#MY?F1[RB+#M^+,F8
MJR<S+2J,8I]8-C`(I)Q!BJ+.-P!Y1&YQ-X#IX+Q<;?;+4_=W2!0^%J2>V4X0
MV@L]=<KHS:4))K?%TJ&9&/I'S&+5/BYQ]M'BQQ^Q/@"QDDDK?Q?9D1;A%R)E
M2/+2J"!59V><@4"[G<Y,*KNE!&H[E:>C7/>[W&HO5X=N-1,E:U$3Y9`>81T5
ML-I8LEE9M=,`"TA,Y<Y`J/G/JCI7/`VWA5RQ$0$0#CWEF@!2H[K*E^@5,`"-
M1UDMJ@_>6AG_`&MO](1\F]2#M&N5SIE>R*I1L`@V0`?$J20B%?21,!$`'PZT
MUT$1(:9Y:OD,<VSWGW-/$GVP:!\*:8J6/.:I?,)O#(6'AH(@7V"VM>`;JFZ"
M4=@_@TL7XC4/KN5L+0/ZI7L1#9?AQ<91;K@'"`0M/M7'LOQ"/--5.UK$[<&&
M)]NOF/DQ<UH1F2Q:/P2&T\?SUQ,(RW8&7414\QBO?DXLF)D34,:-:JB(;%@K
MAND&V953N\+JW_4:)@E$Q@I8S4#QE(CT\HS763=Z$4K6T;:X!65;TED'W4_F
MGRS!/FXQ+IQU[:_$3!6%<<8C/@3$%[OK'M:,B9F\KPQS:EPW'=4]Y0N)V?DY
M>6B'#QRK*2RZRI0,<03(8"%`"E#0\NV\MQWB[U%S75/M-N+DE"%J2`D98`CG
M[8(MBV/MZS6MFW-TK#SZ&P5K6D*U*/:9\I2&0E'M?\B_B)Z>+O'NGI_>?L+_
M`-Q:^'[PW[^W5?\`2K_E1F/NU9/IT%)HX_5IR]$(W"[B"-*<7N/0#4.OZ'[!
M$0H(#4/[Q^("`#ZNFJ?>'<']NK/Z5?SQ/NUM;^QTO_@3\T!(?$'<`;:XF\CK
M>S7B6WF%L89Y%M9%52VX-JVCX*S<HV^BV-<47&,VQ$F\;#W+'.2222!``A5B
MN2D*!>@-!T7W?47J@%DKEJ<J:6?>49DI42H$D\1,CS"%.ZY[38LU]:NU"A+=
M'4@:0G``I`20`.9$_/V1!?BK)UZ87R5867,=2Z\%?6-[HB+QM:40/L,WE81V
M5XFDL%0!9F]3(9!PD-2JH*G*(#71:NM%27*D>MM8D*I7TE"AZ_:("=HN559[
MHBY4:BE]I<P1Y8M)^%7*ZQN9G&G%W(.Q7+8K6](-!.XX9-5,[JTKVC0]QNRT
MY)`#"JW<P\PBH4H&`!.W%-0/8,`BA.X]OO[:O=1:GD*#*'"6YCWD$G2KSC/M
MG'17:E]8W18:>ZTCB55*FT^(`09*EWAZ<NR(`OBIQW<=^*8=`$,VW34!,2OL
MV&XJ`%W;S#U]`"`!XB%0T6OP]_XBK/V!_3@*_B)PL5#^T5ZTI@)90:DK_P`&
MI_6Z:]S+^"84%O(_OD^TQ:2]K\0'M[<,``:UXZ8U-TH/08!N)1\:T&GW](#O
M>7WLN$_[08Z.;#_P=:O^6/R1[SR=X\6#RKP9DG`63&";VT,D6T\@W2HIE.ZA
MY`2^?"W#&&,'Y&5M^721=MS@(452"O01#6%L=UK;%>6[K1X.-D$=LLQY",/7
M&:W#8:3<=G<M-5^K<'H[?-%6IR7X^7_Q7SOD[C]DIJJUO#&EQOX)P\%$Q&T[
M%>PO`W1'`/E`K%W-#N$G:!B^SL5$OB40!_-OWNDW%9$7.WJ"@6P5=AD)S'.<
M<[MS;>K-KWAR@KDR`<4`.R9ECYH?GV@.XK)]OSDLQD[E?.U./V5U8VU,UPQ%
M554(=K[PHE!9*9M"`(GD[)7<&,X,4/,6C%%B#42$UIO4C9;&[;`7V4__`+=A
M/<4.692>P_N\(W/I=OFIVM>PA]6JTO+TJ1PU')6>8X>C&<62T).Q-R0T1/0,
MBSF82;C8^:B)F.72=QLG%23=-VP?L7:`F3<-GC54JB1PZ'(8!#22*:73ON4E
M0TI#S4P9CB,/3SA\6'DU##;S#B7$+`5,&8D?R]4`Y_%)'*;F-QW(`AO)QP5,
M8M2B(`;(5S%*(E`PF`!,0P5$``1`:>`Z:W\/>&W*O]LG]`0H?XBO\24_[.!O
M+`,4M_V$8P@4I;XLPQC&&A2E"YHP3&,(]```T;;O_=U3^R/RP![3_>U-^W^:
M+=F.$IF;:O02M6E?`:"#=/IT$?5KG74I#BG$#BI0CIE3)*D(')ML^V($_B2;
M]AK6[;%PVF\>((S62LMXLMR#8G61*Y>GAIX;NDU6R1CE.HFUC8$QE!"NP#!N
MI4-%?H91UOWT:J*=)*66%@GAW@4CTS,O)`>ZZU]$ULIV@<(\=UY"@.U!2?5A
M#W>T1/1EP]M+AB\AW:+QLWP=:\0N=$Y#>5)0*CN%EVR@%$=BC.08*)F`?`0U
MJ&_6:AC>U=\2"%%S^*"(W/8#U._LFA%$02&P"`<N\9SB20@B)0KZQ^7I4:#]
M\-:F0`9#*-X,A@.4(WH^[_0$.FK%**1,"8XQ:0#*?O#+RQ&=W,^VOBON,896
MM*XS,;1RY:"#R0PWEI)B963M*:72`5868\G:M*V-<"B1$Y!F(B):%72VK)%K
MM^R-ZW3:%Q^,8)7;%^^UP.0G+\X<#QR.$:+O[8UMWO:S2.`(NJ!-+G*4\#V&
M?S<8K=\\X&RAQHRS>>$<T6NZL_(EC2`LI6+<`<[=ZU4,H,=.PC[RRH2UO3+4
MI5VCM,1363/0*&*8H.SMV]T.Y[.FKI5!2<(0:_[=O&V*KX2XH4A?;!?/PI?\
M"','^.7']/N?H^5TOGX@5%5TH)YAAP>MN&F_#GI^Q;AIR\1O_:05_P#L=+O\
MT,;\T-OY80W(JX<!Y`AN)UWVC8.?WS*/3L&[KZC!F+7A7)9A@>57D(TL5."Z
M.>$*Y(B`M%@!8Q1$O369VZY:6;RVN\H4];1/6D&4S(RQFDYRR(PC`[D9NE19
MG46=WP+@2-*E!1D)C5[J5XD3EW3C`$O/KC9R.#*;,>X+W#;1-?AP=&M@F4\4
M\X0MI)L)A]Y3Q_\`5/%W[!"V#]L^J!,%*;A'39['O=F32+&T[-4J9U=[PWJ7
M/M\2I"IRY0H&]+!<?BT_>R^L^/+#6S72S_Y.6?FCR_AQQMOD<]6B'";N%XP+
MGT$7@P`XKQ5SC&?&*`A/K,LT`\731GV8,7;[U]9T85IY@@--9'>=]H18U'=U
MDKC:9#WGJ0',2EX=5XF?YN,>&R;!5"_-_<^^TINTS+2S5:?=,YZZ,-Y3][#S
MR@U+@IC[NW6=D!=?G+GOC]EO$`61(-8=ACRSG-O7[]M3R,2>*DIAVK9%H)&C
MT8LCPJR8E*H*IR")1I4%CW;<=BU-&C[IT%535NKO:G-0E_">6/1#1;5H.H%+
M6J^]%<S4T>G#2C3CP]UELCSSB6<M-H5]05\:5H'WM:()]L^W."%CI&N4Y?EG
MCZ8R7;4VWQZ5\:>FGCTU8):CG/SQ7"6$I=DODCH656N17V,L@LL12<)"94=V
M=<;;',Q<S87ENQ5ZK1+I.V9&<:$1<F<Q#.8,BHX3!-03I%,&T:TU]M`NC;KF
M5W!*ET`=27$I,E*0%#4$F8D2F8&(QXB/DKT5CE"\BWJ2BO+2@VI0FE*R#I*A
M(S`5(D2.'"!4.=F`^^!+X.N]3D_SEPK:^$B0RPY"0PSBW-"K12W]G]\2W..%
M<#7/>(6Z*-??-YRM/*KYM"5T==M7KI0BY-_8UGK5W?5W-;J1WN$O$J0B<`+=
M=FZJ+MSOVO=J1%ITG7I;41I[?#I2J!D0XVX$`"[>X5QA$FTNP2XJYM`79M#;
M3;Q>I3;I@$7Z]E`*K)7@RR#U#+L_XOE"VKV_MG69WVDU3,_J:[/C_P`'SA?R
M;L#=*=PKC*'M%^ABKF[6M>E:<7OHU\:]->J+[>]7<LM?/M>H)>NKE'HQM_;<
MSHOM'E_,UOJ_J<Y^3&)R^VMQV[IS2R".>`7/RP93#97;CW"/N+%G)TF'%7'F
M"#L+4-FKC9&6P4HK[O,&'7`GF5KUKH-[PO?3PW,_>JS50N6,Y/4\^W]352_+
M"#3LFP[Z%O/W4O;1H,,V7P.,O]XI/1A#`^?O''*BG).\5>?/<%PBAR#4CHX\
MRWO#%7,$6R-KF!P:(2M4UL<9%[-^Q:?Y4K?ZI.=EO\P=PJ;];QLV^6\60?=&
MRUAL^HY/4?O8SGXE5KYYQHN];!5F\_\`=]\8%VPE-FJ[)2\*C*9Y2EYHGY[>
M^%.]1;F.<'.+&YCX,OWBV@\LIRP89*QME9C>3W$R<@Q.\C[5<Y9PS9U]MR+V
MV50L8=[^1`IDQ3."8!H*;RNG39ZJK@NV536X2I4YN`I#N,S]6^IO//3,0=]D
MVKJ>Q140I[G2/;>\,:9MR7X6$A)=.AS+*<E<YP40L8P?13`X"/ZXP!0:^FH@
M&W0)FT3J`(J.`QQ/#$89]L&\%`!"P2T<SA(#CF9^@>2!*N%.-.W+#][[-]^8
MWY&6!=MT2TI?I<,8/9V1E2-D;5S6^!?],QR7;.X_BL8OV4(5G(?4@1TR[%?W
MU3RMPHEW,7NNOWV]TKI*:YT(9M20GQ'O$;4M:9C22D.%8GA/N`\X7/:MNV-3
M]3ZFKI;@T_7%1+3(;J$E*I'#4MI+4QC(^(0>$%JF-M*<4B&4.&T1+6@F$!`:
M`*AB%"H=/'2^$K2A,P2GLEEPSD885@-J?7X)`5QU:I3]!]4#`=Q;"_>=N/$7
M(E3)O,'C78'$=<]XNYYM:&-LC/[V98;6DGBC.+N1SCC$-XWHL@TMTR2<JHP(
M8#D*H*B@I"(Z.&UKITNIWZ1#=MKZB_:DR5X@2/$[`I]*,3B)B7G@*;JM?4NJ
MM]<JKN='36.1!'AZIM<^[3K<[,Y\A*!,`XW8%VAL[A7&';0*`7%7-GRZ4Z;:
M<7]NVGA3I33&F^W33C9:_3/^>H<_^JA7&MO[=\4Z+[2>+CFS6_+1RB5GM?<=
M.:*$MF@>VMS_`,&NW2EL12.7"Q.*^2H0R#-3ZR"VW0_I-XU,H<UU(?G0L08F
M/)"7?M()=#_?U\VP7:;[\V:M#FD^#-ZFRD)_J:J64O>@E=/[#N%+53]Q[W3*
M:F/&TM/#C_KJ.>?YL,%RMQL(&;[O#,G<,Q8;D,%\`%X'O#%//7])QLA>]-O=
M#K@XXNDF0G?>?(]R\F@T\KR`V[-;-;KXQ]W@+=9:S[!\(2*7J+W)83_K6O+F
M)QK-WL"3N&=ZOE,+WXID"S5^]JR$J31*?;*#%^!.*.]'9MXXF=\B.46%,M\;
M6S1<UVQ$C85U0N:9*)4@GI(%,']Y8PL.Y$'Z$F+8ZPR0)NA2`0/41TN&\[CT
MSJJ)T62WU=->@HR)6%)49X^X\M`D>P=D,SM*V]2:1^E-SN-/56,@3^K"2$`"
M7O,-NXB4L3E$[@"8`"H`/7VMPE`0"O6FT:>&A&9$@IF!QGKGZL(+'?2"%S5Y
M)2]<H;?RRB.4$]A2X8OAS=N.[&SPM(VZ>VKERG%J3-ELXQ&;9J7*C(1[=A*+
MJN74$5=-N((&`JQBC4*5UF]NOV-F\)5N%A]ZT@'4$*(),L,E)5GVB,%N!F\/
M6I2=NNLLW68TE821+CFE2?5`=_=KX_\`<*DX7%CGN5\[>--O67]I90N,V$%B
MW.YK-&[1B@&04,;$/'VY$@G0A-X$"07W>[^9Y84\P=,CTYO.QT7!X;&M%>NY
M2^L^M;RX?[Q4@2E+*%GZF63=CM/3*WY>*-NBF?!'A+(G]+_=Z4X_OB3E+"40
MG_R;L$T-_P"(5QBI3K^]5S:\:]*5XO5W5\*=:^&BRJ^W/4=5EKYZL?KJ'/\`
MZN`TG;^V=?=OM)J_8UW_`.'$Q7:EX]<_(Z2OYYVU.>F#)VWDW3#](T5(8LY,
M$Q(O,^Z$]Q]^/E?CK!6<%V?5VRON3I.1]WV;PV;=#;J#?-H%YO[[V6L%5I[D
MGJ;5*7^HJB?3[8,G3&P[G13/'8E[IE4L^_-E\"<SD:BD';[OFC;NU<?>=<I*
M8I>=S/G?QTMV.,:?+B6*B<6<AE+!3D019_:%1@KB7CW<4,-PF9^3Y@/G)GON
M_P!$/+KKXNFE[VDFH>^Y5FKC6R^L^N9RF?Y^I`SGE'GU,LVZW*=@;XN]$W1_
M^G)MTC_Z-*3RSB'+^3;@?V:]POC'MH-/WJN;/AZ:UXO4I3QKHL&^WK29V2OU
M8_\`K4.7_50'CM_:X0=%]HR9B?U-=GP_X/V04]VXL*=Y>WL#X./QYYC\9KZX
MG$5A7-G(WOC3)K.>6QH2:*>3CK25R9AVSKQ3B5HX%R1AW(>[@`E%`X)T'2X;
MKNO3=^MJV[A;*QB^$*U*+@5)R6$PV^I.)EP(YX0T&T+;U,8MM"JCN%&]9`!H
M`1(EJ8F>_3I5ES(5RQ@K(1/01$HUI]`1+0*=*@)1'Q\0ZZ!TW%)^K`2J?TOW
M)P=T^(E6!*L/HY3_`(4H$,^(RQAPWR%D_$CB=Y*8VP-RLAK:*G<D?>%D9DNJ
M/O#$+]P_&!<SSO#^-<A+PT]`S;=4(XKTJ2KEFX6V@*9"F!CNAM?NFCH:KX*A
M>J[&2?=73H(<^E+QG6U$9983G"T==+?M2MK6/M.O:H[O(3FBH6"CZ)/A-.)G
M+Y.R!I0XW8(\L_\`XA7&'R_V[=BKFO3QZ5W\7_H>NO3UZ.=/?+N*9?P]EN!1
MCKF[02'DG53E+E`$;V_MI+O]7OU(IW#3]37#VT<IS\_*"2^W'@KO,0W'2WQX
M:<V>/=V<=USNOT?AEC&&;48]DP*J?S?L&.9,'6K<YK65<"IY'N_G1@"`^3TK
MH!;NO73DW-7V]9ZH7/CH>:G_``O!J2G+GC#"[*M'4Q%G2+!=:9=LGW2MMP&?
M9XU,%2]7JB+;N6<=<^.>2RSGN)\_N/T?GA:SX<\6P>XKY3#`-;%%9[]5I6@;
M'?&R2LHT.5][QYHLW"IA=>9YP^;NT0>GE\LZ;,H;*LU<:"?>^NI_>Q_GJH*_
M+R0.NH]DNSEV0=\WFC;K=(T_5/G#_P!BD*>6<1^)\;<&;R>5W"N-?G^8D#?W
M3%7-X'0.!5+[L+7RN+WG>]`OM\K94_F4IUIK<ZZ^W4TK@J+)7AK1W_KJ'+S5
M4_1&B,6"PIK&C17RC55>)W/J:WW_`.%22])E!A>*L,_$01N.[/9VYS`XAS]O
M)6[$A!RN0L978E>;F%]Q2^JS7`2>Q5!SY9+W42^9]8-2/=P?E@W5TM[UVZ/+
MJ%_$6NXH="S/2X#,SQG_`%B7HPAJJ2U=8_!2$W.@U>&F1T)RQT_\-^[SB%+N
MH\=N;+R_K"==RWGWA.*D%F4Q^C&-_19R>/C1H4"M?KP;4-BGC=*V,>?%OY7O
M8"Y4DO=Z;_R>BKTVO6VD/N#I_9ZY=3AJ)=I@>S]?5#U0(.I-BOZUM_?R]4J!
M]#ZE\B4_]32%,I^N''=K'`'=+B<3S#GMY<Z\$W-@LUQR)2L+UQ;GY+'"=U@`
M?7"EHFS-@"VB&5,X$/K#ZH7%(%@'S0\W6L[VNO3U=W_[OME>B]2.O2XR><OU
M-24QL_3VR]046H?=*[TB[3K$]32QA,3EXU*%3ERQ@R?$3;)#+%V/VF8I*!F,
MK-K1@4,C2UKMS-+;DKS2CD"7$^@FID6YF\2ZE`4.W(*9!*D(`)0'II<ZY=(Y
M6.KH$.-T1<5X:5D%81/NA1!4)REQ,,G;FZUJB;;N+B':X)[ZT`A*E<2`0D@>
M81Z&;;TW5\>E*^-/DU\PGPCZ7-$AKGGV_)&IO+VCNIMH-:U\*=?E\-6(TR.G
MW>.?Y>B/5$Y]SWO7`VWQ`5B=N^_L;VG$<A,WVO@GE:T@Y:4P+=GV1OF\YV4B
M61M[NU\@16.;2NR>0QO-R'Y-)V\12*T?"*C4QS%72.;.C]3OBD6IS;U.:JPE
M2=:5J;0D=J"XI!)`]X)..&K&4`KK33[$J:,)W.^*:]A)\,H2XHD\E!M*DC'G
M[)QX;\*@3R\*<Q""JDMLS38A`50!4$%2EL)<I%$07317\I0@`8N\A#T'VBE&
MI0RG7PK5<:!3@"5EAR8'#]7AVQAOPZAL6BXADDM!UN1/$?68P5Y^QTOGS0QG
$S1__V3\_
`
end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
